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ABSTRACT 
The purpose of the study was to explore the relationship between patient adherence to 
secondary prevention therapies post an initial episode of acute myocardial infarction (AMI) and 
subsequent risk of cardiovascular events by using time-invariant and time-varying measures of 
adherence.  The effectiveness of both measures in predicting a (i) recurrent AMI, and (ii) 
mortality using various mathematical models and statistical techniques was compared.  Time 
dependent confounding was accounted for by using marginal structural models (MSMs). 
A longitudinal cohort observational study design was employed using the retrospective 
Medicare 5% random national sample claims data from January 1
st
, 2006 to December 31
st, 
2008.  
The time-invariant measure of adherence was measured over a fixed one year period.  Time-
varying adherence was measured quarterly along with other time-varying confounders over a 
maximum follow-up of 11 quarters.  Estimates of the effect of adherence from Cox regression 
models and MSMs were compared, along with model-fit-statistics. 
Of the total 1,427 patients included in the study, cohort A (statin therapy) comprised of 
1,091 patients, and cohorts B (β-blocker therapy) and C (angiotensin converting enzyme 
inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy) included 1,021 and 1,025 patients, 
respectively.  When accounting only for baseline covariates in a discrete-event time model the 
hazard for a recurrent AMI among statin adherent patients in cohort A was 63% of the hazard 
among non-adherent patients (Hazard Ratio (HR) = 0.63; 95% CI [0.40, 0.99]; p = 0.0471).  
When accounting for baseline covariates and time-varying covariates in a discrete-event time 
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model the hazard for a recurrent AMI among statin adherent patients in cohort A was 61% of the 
hazard among non-adherent patients (HR = 0.61, 95% CI [0.38, 0.97]; p = 0.0366).  The results 
for the effect of adherence to β-blockers and ACEI/ARBs on subsequent cardiovascular events 
were not statistically significant.  The stabilized weights used in estimation of the MSMs did not 
have optimum variability and the results from the MSMs were not statistically significant. 
Further studies are required to understand if MSMs should be the preferred methodology 
when exploring the relationship between long-term medication adherence and health outcomes. 
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CHAPTER 1 
INTRODUCTION 
Adherence to Secondary Prevention Therapies Post-Acute Myocardial Infarction 
Cardiovascular disease (CVD) continues to be responsible for the most number of deaths in the 
United States (U.S.) every single year since 1900, with the exception of 1918 (Roger et al., 
2012).  The economic burden of the disease too, is crippling.  As per the Heart Disease and 
Stroke Statistics 2012 update, acute myocardial infarction (AMI) is one of the major contributors 
of the morbidity, mortality, and economic burden attributable to CVD (Roger et al., 2012).  
Clinical guidelines recommend indefinite treatment with statin, β-blocker, aspirin, and 
angiotensin converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker (ARB) therapy 
post-AMI to prevent recurrent AMI and mortality (Smith et al., 2011).  Even though multiple 
clinical trials suggest that secondary prevention therapies post-AMI are beneficial (see 
Hennekens, Albert, Godfried, Gaziano, & Buring, 1996 for a review), meta-analysis of 
observational studies suggest that long-term adherence to these drug classes is not optimal 
(Naderi, Bestwick, & Wald, 2012).  The recent meta-analysis reported a summary estimate of 
57% for adherence to primary and secondary prevention therapies among patients with CVD.  
Patients who had at least 75% of days covered for a specific drug over a specified time period 
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were classified as adherent.  Among AMI patients only one third were found to adhere to 
secondary prevention therapies. 
 Given that long-term adherence is suboptimal, it is essential to understand its effects on 
subsequent outcomes.  However, it is not possible to explore this relationship using clinical 
trials, as subjects cannot be randomly assigned to adhere to drug therapies.  Observational studies 
are the most feasible, economical, and pragmatic tool to measure long-term adherence among 
real-world patients and its association with outcomes thereof.  There are several observational 
studies that aim to explore the relationship between use of secondary prevention therapies at 
discharge post-AMI and outcomes, and report beneficial effects of therapy (Ho et al., 2006; 
Jackevius, Li, & Tu, 2008; Lee, Cooke, & Robertson, 2008).  These studies, however, have not 
measured long-term adherence and its effect on subsequent outcomes.  They have defined use of 
secondary prevention therapy as possession of medication at discharge, or 30 days after 
discharge.  The association between use of secondary prevention therapy as described above and 
outcomes measured over a year after discharge cannot be termed causal.  There are a number of 
other factors that could lead to the outcomes over the year.  Studies that have measured long-
term adherence generally compute it as a constant medication possession ratio (MPR)/proportion 
of days covered (PDC) over a year post-discharge.  The association between this long-term 
adherence and outcomes over the entire period is then reported, which sometimes extends to five 
years or more, while adjusting for baseline covariates (Newby et al., 2006; Rasmussen, Chong, 
& Alter, 2007; Amin, Mukhopadhyay, Nathan, Napan, & Kelly, 2009).  In other cases the 
adherence is measured as a constant over a certain period of time, and its correlation with 
outcomes measured during the same time period is reported (Wei et al., 2002).  Studies have also 
reported the association between persistence and outcomes (Gislason et al., 2007), where 
3 
 
persistence is defined as time to break in therapy for a pre-defined number of days which varies 
across study designs.  However, it has been shown that some patients resume therapy after a 
break. 
 One drawback of trying to study the effect of long-term adherence on subsequent 
outcomes using the above methods is that medication adherence is not static.  It is a dynamic 
process that may change over time due to the effect of intermediate events.  To my knowledge, 
there are not many studies that have modeled adherence to secondary prevention therapies post-
AMI as a time-varying predictor to study its effects on outcomes.  Studies that have attempted to 
do so have used the Cox proportional hazards model with adherence as a time-varying predictor 
(Ho et al., 2008; Levy, Tamblyn, Abrahamowiez, Mc Leod, & Fitchett, 2004), which seems like 
a simple solution.  However, it has been suggested that using this approach will not provide 
estimates with a causal interpretation in the presence of time-dependent confounding (Robins, 
Hernan, & Brumback, 2000; Hernan, Hernandez-Diaz, & Robins, 2004; Hernan, Robins, & 
Garcia Rodrigues, 2005).   
Time-Dependent Confounding 
In most health intervention research, the exposure varies with time and so do the covariates.  In 
most cases, the time-varying confounders are outcomes of previous exposure.  They are also 
predictors of subsequent exposure and outcomes.  Therefore, these variables are interrelated and 
form a sort of feedback loop or cycle.  However, most researchers ignore this and study these as 
independent variables while trying to estimate the causal effect of one on another.  This is 
applicable in the case of studying the effect of medication adherence on subsequent outcomes 
(Morris & Schulz, 1992).   
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To understand this phenomenon and how it might lead to biased results in our case, 
consider the longitudinal effect of disease severity while studying the effect of adherence on 
subsequent outcomes (Figure I).  Disease severity is a dynamic measure; however most 
researchers adjust for the number of hospital/emergency room (ER) visits, concomitant 
medications and so on, as a constant variable measured over the entire study period.  Based on 
prior literature, medication adherence (at any time t), is a behavior that reduces the risk of 
subsequent mortality (at t+1).  Disease severity is associated with adherence at t and also the 
subsequent risk of mortality, making disease severity at t-1 a confounder.  Additionally, 
medication adherence at t has an effect on disease severity at t+1, thus disease severity at each tn 
is related to prior exposure.  Therefore, here a crude estimate between adherence at t and 
mortality at t+1 will be biased as subjects with low adherence measures at t will tend to be those 
that differ in disease severity at t-1 and have a higher risk of mortality at t+1.  The estimate 
obtained after adjusting for disease severity at t-1 will be biased as it does not account for the 
fact that after the start of the study the level of  adherence may change according to changes in 
disease severity and vice versa.  Even controlling for repeated measures of disease severity may 
not be the solution to the problem, due to the presence of the feedback loop where disease 
severity is on the pathway between adherence and mortality (Cole, & Hernan, 2002; Greenland, 
2003; Hernan et al., 2004).   
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Figure I Longitudinal effect of time-dependent confounders. DS(t) and DS(t+1) represent 
disease severity at time t and t+1, respectively. Similarly, A(t) and A(t+1) represent 
adherence at times t and t+1, respectively. Z denotes the outcomes and BC stands for the 
baseline covariates which includes DS(t-1). 
 Since traditional methods that have been used predominantly in the literature do not 
account for bias due to time-dependent confounding, a relatively new estimation method – 
marginal structural models (MSMs) was developed and proposed by Robins and colleagues 
(Robins, 1999; Robins et al. 2000).  Inverse probability of treatment weights (IPTWs) are used in 
the estimation of MSMs, where the inverse probability of receiving the actual treatment given 
prior covariate history are used as weights that essentially produce a pseudo-population.  This 
accounts for the time-dependent confounding, as the adherence at a particular time is no longer 
predicted by the covariates, enabling one to generate an unbiased estimate of the effect of long-
term adherence on outcomes.  In addition to the patient-specific weights, time-specific weights 
adjusting for study discontinuation are used in the final model.  The use of these models in the 
literature has been scarce so far.  Studies that have employed this technique, however, have 
reported differences in estimates with MSMs and those obtained by traditional methods (Hernan, 
Brumback, & Robins, 2000; Bodnar, Davidian, Siega-Riz, & Tsiatis, 2004; Teng et al., 2005; 
A(t) 
DS(t) 
A(t+1) 
DS(t+1) 
Z 
BC 
Time 
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Cole, Hernan, Margolick, Cohen, & Robins, 2005).  They recommend the use of MSMs in the 
presence of time-dependent confounding.   
Needs Assessment 
Considering the above, the estimates of the causal effects of adherence on subsequent outcomes 
may be biased due to time-dependent confounding.  There has been only one study that uses 
MSMs to estimate the effect of β-blocker use on subsequent mortality (Delaney, Daskalopoulou, 
& Suissa, 2009).  β-blocker use is not a time-varying predictor in their study and the clinical 
measure of blood pressure is the only time-varying confounder that was modeled.  The objective 
of this study, however, is to measure the effect of long-term adherence to secondary prevention 
therapies post-AMI on subsequent outcomes, and not the effect of the use of the drugs at 
discharge on outcomes.   
 With the economic burden of the disease being high, and the suboptimal levels of 
adherence to secondary prevention therapies, it is imperative to try and obtain an un-biased 
estimate of the effects of long-term adherence to secondary prevention therapies post-AMI on 
subsequent outcomes.  Additionally, it is important to understand the extent of the protective 
effect of adherence while designing interventions and disease management programs for patients 
with AMI.   
From a methodology perspective, too, this study is significant.  As mentioned before, 
observational studies are the most suitable for studying the effect of long-term adherence on 
subsequent outcomes.  A meta-analysis conducted by DiMatteo, Giordani, Lepper, and Croghan 
(2002) identified 44 articles that explored this relationship.  The authors stated that the studies 
were all co-relational in nature, and hence there is a need to perfect the methods used to explore 
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this relationship.  Gu (2011) used Cox proportional hazard models and pooled logistic 
regressions to investigate the relationship between adherence to antihypertensives and 
cardiovascular outcomes with adherence measured as time-constant and time-varying.  Various 
models were compared and it was concluded that both measures were similar in predicting 
adherence.  However, the study did not account for time-varying confounding.  Similarly, Yu, 
Yu, and Nichol (2010) have compared various models using adherence to hypoglycemics as 
time-constant and time-varying predictors to predict outcomes among type 2 diabetes patients.  
They found that the various models yielded very different estimates among which only estimates 
from MSMs suggested a reduced risk of complications among patients with higher adherence 
measures.  From above, it is evident that there is a need for additional studies among patients 
with varied chronic conditions to determine the best methodology required to explore the 
relationship between long-term adherence and subsequent outcomes using observational studies.  
Study Aims 
The broad purpose of the study was to explore the relationship between patient adherence to 
secondary prevention therapies post an initial episode of AMI and subsequent risk of 
cardiovascular events by using two approaches to measure adherence.  A time-invariant and a 
time-varying measure of adherence were computed and the effectiveness of both in predicting 
subsequent outcomes using various mathematical models and statistical techniques was 
compared.  The specific aims of the study were: 
1. To explore the predictors of patient adherence to secondary prevention therapies post-
AMI. 
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2. To explore the relationship between adherence to secondary prevention therapies post-
AMI measured as a time-invariant variable and the risk of subsequent outcomes. 
3. To explore the relationship between adherence to secondary prevention therapies post-
AMI measured as a time-varying variable and the risk of subsequent outcomes. 
4. To compare the effectiveness of measuring adherence as a time-invariant and time-
varying predictor of subsequent outcomes. 
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CHAPTER 2 
LITERATURE REVIEW 
Health and Economic Burden of Cardiovascular Disease and Acute Myocardial 
Infarction 
An estimated >1 in 3 Americans have one or more types of cardiovascular disease (CVD), which 
accounted for 32.8% of all deaths in the U.S. in 2008 according to the 2012 update of the Heart 
Disease and Stroke Statistics (Roger et al., 2012) released by the American Heart Association 
(AHA).  In the past century, it has been the leading cause of death in the country consistently, 
based on the estimates from the National Center for Health Statistics (NCHS) and Centers for 
Disease Control and Prevention (CDC).  The estimated direct and indirect cost for CVD in 2008 
is $297.7 billion and is projected to increase to thrice that figure by 2030 (Heidenreich et al., 
2011).  Thus, CVD and especially, AMI remain a burden to the country in terms of costs 
accumulated and mortality rates.  The overall prevalence for AMI is 3.1% in U.S. adults, over 20 
years of age, based on the data from NHANES 2005-2008, with the prevalence in men (4.35%) 
being slightly higher than that in women (2.2%) (Roger et al., 2012).  As per the 2012 update of 
the Heart Disease and Stroke Statistics, the estimated annual incidence of AMI is 610,000 new 
attacks and 325,000 recurrent attacks with the average reported age at first AMI being 64.5 years 
for men and 70.3 years for women.  Approximately every 34 seconds an American will 
experience an AMI and ≈15% of the patients that experience an AMI will die of it (Roger et al., 
10 
 
2012).  Additional computations suggest that an approximate of 16.6 average number of years of 
life are lost due to AMI.  Age-adjusted hospitalization rates for AMI are reported to be 242 per 
100,000 people from 2003 to 2005.  The in-hospital and 30-day AMI mortality rates, however, 
have declined over the past decade based on reports from several studies (Chen et al., 2010; Fihn 
et al., 2009; Roger et al., 2012).    
 From the above statistics it is evident that AMI is a common condition with high 
mortality and morbidity.  Therefore clinical guidelines, based on evidence from clinical trials, 
recommend the use of statins, β-blockers, aspirin, and ACEI/ARBs for the management of 
patients with AMI (Smith et al., 2011) in addition to lifestyle changes.  Between 1980 and 2000, 
increased use of evidence-based therapies were responsible for an approximate 47% of the 
decrease in deaths due to CVD, whereas ≈44% decrease was attributable to changes in lifestyle 
and environmental factors bringing about a change in the risk factors in the population (Ford et 
al., 2007). 
Adherence to Secondary Prevention Therapies post-AMI 
Many studies have documented non-adherence to secondary prevention therapies post-AMI.   
Almost a decade ago, Bradley et al. (2001) suggested that less than half of post-AMI patients 
received β-blockers at hospital discharge.  A recent analysis conducted using administrative data 
in Ontario, Canada found that approximately 27% of all prescriptions are not filled within 7 days 
of hospital discharge after MI (Jackevius, et al., 2008).  Specifically concerning cardiac 
medications, 8% of patients did not fill their prescription for beta-blockers and only 44% filled 
their antiplatelet prescription.  Contemporary U.S. data provide similar findings (Fischer et al., 
2011).  This is an example of primary non-adherence (Rashid, 1982; Vermeire, Hearnshaw, Van 
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Royen, & Denekens, 2001) whereby the patient fails to fill the initial prescription at the start of 
therapy and is seen by some as a more severe form of non-adherence (Jackevius et al., 2008).  
Using data from commercial health plans, Lee et al. (2008) reported that of 1,135 members with 
Acute Coronary Syndrome (ACS, including unstable angina as well as AMI), 52% had at least 1 
pharmacy claim for an ACEI/ARB, 64% for a β-blocker, 63% for a statin, and 30% for all three 
key drug classes, during the three month follow-up period.  Among patients that started aspirin, 
statin and β-blocker therapies post-AMI, it was reported that about 34% stopped at least one 
medication and 12% stopped all three within 1 month of hospital discharge (Ho et al., 2006).  
The study used a prospective cohort design and medication discontinuation was determined 
using telephone interviews.  Initiation of secondary prevention therapies post-AMI is still 
suboptimal as suggested by the above studies.  However, a considerable increase in the use of β-
blockers and ACEI over the years has been documented (Gislason et al., 2005; National 
Committee for Quality Assurance [NCQA], 2006; Rasmussen et al., 2005) with the publication 
of guidelines that advocate the extensive use of these agents post-AMI.  Several organizations 
have also taken the initiative to increase prescribing of evidence-based medicine at hospital 
discharge associated with an AMI.  These include the American College of Cardiology (ACC)’s 
Guidelines Applied in Practice (GAP), “Get with the Guidelines” by the AHA, the Joint 
Commission on Accreditation of Health Care Organizations (JCHO)’s quality check, and the 
National Committee for Quality Assurance (NCQA)’s Health Plan Employer Data and 
Information Set (HEDIS) (Labresh et al., 2004; Mehta et al., 2007; NCQA, 2003).  
Even when patients fill their initial prescriptions post-AMI, data suggests that they have 
low rates of long-term persistence (Ackincigil et al., 2007; Butler et al., 2002; Frohnapple, & 
Mehta, 2002; Kramer et al., 2006; Lee et al., 2008; Mitra, Findley, Benner, Glynn, Mogun, 
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Neumann, Weinstein, & Avorn, 2002; Newby et al., 2006;).  These studies, however, have used 
different methodologies and definitions of long-term persistence.  Self-report of consistent use of 
cardiac medication over 6 to 12 months was low (Newby et al., 2006).  Approximately three- 
fourths of the patients reported persistent aspirin use (71%), whereas less than half reported 
persistent use of β-blockers (46%), lipid-lowering agents (44%), and all three medications (21%) 
after diagnosis of coronary artery disease (CAD).  Butler et al. (2002) analyzed prescription data 
of Tennessee Medicaid enrollees post a hospital discharge for AMI.  If the subjects had not filled 
their prescription in the prior 30 days at 180 and 365 days post discharge, they were considered 
to have discontinued their prescriptions.  The authors reported that 63% and 61% of patients who 
were discharged on β-blockers were current users at 180 and 365 days respectively.  Mitra et al. 
(2002) analyzed clinical data over a 24 month follow-up period and found that the percentage of 
patients receiving aspirin, β-blockers, and ACEI had fallen to 88%, 71%, and 43%, respectively, 
whereas use of lipid-lowering agents slightly increased.  When therapy discontinuation was 
defined as a lapse of 60 days or more after exhausting the cumulative days supplied from prior 
prescriptions, Akingicil et al. (2007) found that 32% of the AMI patients discontinued ACEI 
after a year and 50% at 2 years. The rates for β-blocker discontinuation were found to be similar.  
Their approach provides a more conservative definition of discontinuation that allows for error 
due to occasional use of medication samples or billing problems.  On analyzing health plan 
records from members of 11 health plans, Kramer et al. (2006) reported that only 45% of the 
patients were adherent to β-blockers (defined as prescription claims covering ≥ 75% of days) for 
360 days post discharge following an AMI.  The biggest drop in adherence was between 30 and 
90 days with participation in Medicare + Choice product, residence in the Southeast, and 
younger age being statistically significant predictors of lower adherence.  Among Medicare 
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patients enrolled in a pharmacy benefit program only 42% were found to be adherent with their 
prescribed statins after 2 years (Benner et al., 2002).  During 18 months of follow-up, Lee et al. 
(2008) reported that 65% of patients diagnosed with ACS had at least 1 pharmacy claim for an 
ACEI/ARB, 76% for a β-blocker, 77% for a statin, and 46% for all 3 medication classes.  
Looking at trends in adherence among elderly Medicare beneficiaries between 1995 and 2003, 
Choudhry, Setoguchi, Levin, Winkelmayer, and Shrank (2008) demonstrate a modest but 
statistically significant improvement in adherence to statins and β-blockers over time.  However, 
the overall rates of adherence still remained suboptimal. 
 Non-adherence to secondary prevention therapies post-AMI has also received attention 
globally.  A cohort study using administrative data from Ontario demonstrated that only an 
approximate 40% of 22,379 subjects were still taking statin prescriptions 2 years post discharge 
for ACS (Jackevicius, Mamdani, & Tu, 2002).  Subjects were defined as continuing therapy if 
they had at least 1 claim for a statin prescription every 120 days after the index prescription date.  
Cardiac drugs were found to be under-prescribed to elderly patients with AMI using Quebec 
administrative data (Simpson, Beck, Richard, Eisenberg, & Pilote, 2003).  However the results 
suggest that once prescribed, patients are likely to adhere to these with high rates of compliance 
and persistence over one year with 60-80% continuing treatment.  In Denmark, Gislason et al. 
(2006) reported that after 5 years of treatment 58% of the survivors were still receiving β-
blockers, with 74% and 82% still on ACEI and statins respectively.  Therapy discontinuation was 
conceptualized as the first break of 90 days or longer.  In Estonia, only 40% of the patients who 
suffered from AMI (n = 4,025) were treated by a combination of β-blockers, ACEI/ARBs and 
statins (Marandi, Baburin, & Ainla, 2010).  Supporting the above results, Sorensen et al. (2008) 
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found substantial underuse of clopidogrel treatment in patients with MI without a percutaneous 
coronary intervention (PCI) using prescription claims in Denmark. 
The above numbers are difficult to compare, as studies use varied definitions of 
adherence and persistence.  Subjects are known to restart therapies even after a break of 90 days 
or more (Gislason et al., 2006).  With this fact in mind, the corroborative results from the studies 
enlisted above still paint a dismal picture of the current state of the secondary prevention 
regimen post-AMI.  A recently published meta-analysis of 20 studies (Naderi et al., 2012) 
assessing adherence to primary and secondary prevention therapies among patients of CVD 
reported a summary estimate of 57% of adherence across all studies after a median of 24 months.  
Patients were classified as adherent if they had at least 75% of days covered for a specific drug 
over a specified time period.  The meta-analysis suggested that approximately one third of 
patients with a history of myocardial infarction do not adhere to secondary prevention therapies 
although the maintenance of these therapies indefinitely post-AMI has been recommended 
(Smith et al., 2011). 
Association between Medication Adherence and Outcomes post-AMI 
Several randomized trials since the mid-1980s and meta-analyses of those clinical trials (see 
Hennekens et al. [1996] for a review) have suggested that secondary prevention therapies post 
AMI improve survival and reduce the risk of reinfarction.  The number of observational studies 
is comparatively fewer.  Jackevius et al., 2008 reported that the 1-year mortality rate was higher 
(odds ratio [OR], 1.80; 95% confidence interval [CI] 1.15 to 1.79; p<0.0001) for patients who 
did not fill all of their recommended discharge medications within 120 days after the index date 
versus those who had filled none.  Similarly, medication therapy discontinuation at 1 month was 
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also associated with higher 1-year mortality (hazard ratio [HR], 3.81; 95% CI 1.88 to 7.72) (Ho 
et al., 2006).  In the Korea Acute Myocardial Infarction Registry, administration of all four 
recommended classes of prevention therapy at discharge was found to be an independent 
predictor of 6 month mortality using a Cox proportional hazards model (Lee et al., 2010).  The 
above studies have explored the relationship between administration of secondary prevention 
therapies at discharge and outcomes. 
 In contrast to this, a number of studies have reported estimates of the effects of long-term 
adherence or persistence to one or all of the recommended drug classes on outcomes such as 
recurrent MI and mortality.  Self-report of consistent use of aspirin, β-blockers, lipid-lowering 
therapy over 6 to 12 months was associated with lower adjusted mortality over the seven year 
study period (Newby et al., 2006).  Wei et al. (2002) report an adjusted relative risk of recurrent 
MI of 0.19 (95% CI 0.08 to 0.47) and all-cause mortality of 0.47 (95% CI 0.22 to 0.99) for those 
who had 80% or better adherence to statins, compared with those not taking statins.  The study 
was conducted using 5 years of administrative data in Scotland and adherence to statins was 
computed beginning the occurrence of the first AMI to the end of the study period.  Amin et al. 
(2009) studied the association of non-compliance with evidence based medical therapies after 
AMI on death and recurrent MI in a population that comprised of greater than 80% minority race 
groups and greater than 70% uninsured.  Non-compliance with ≥4 evidence-based medications 
was an independent factor associated with death or recurrent MI (HR, 2.83; 95% CI 1.60 to 
5.01).  Rasmussen et al. (2007) categorized adherence to statins, β-blockers and calcium channel 
blockers (CCBs) computed over a year post discharge into 3 categories – high (PDC, ≥80%), 
intermediate (PDC, 40%-79%), and low (PDC, <40%).  They report a dose-response type 
adherence-mortality association for statin and β-blocker users, where compared to their high 
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adherence counterparts, the risk of mortality was greatest for low adherers and intermediary for 
intermediate adherers.  Long-term mortality was assessed till the last available follow-up date 
(median, 2.4 years).  Similarly, good adherence i.e. >80% to β-blockers computed over a year 
post discharge following AMI, was associated with a lower adjusted relative risk (RR) of 
mortality (RR, 0.49; 95% CI 0.30 to 0.80) compared with patients not on the therapy over four 
years of follow-up (Wei, Flynn, Murray, & MacDonald, 2004).  Non-persistence, defined as a 
break in therapy of 90 days or more, with β-blockers (HR, 1.25; 95% CI 1.19 to 1.32) and statins 
(HR, 1.88; 95% CI 1.67 to 2.12) was also associated with increased mortality (Gislason et al., 
2007).  Shaya, Gu and Yan (2008) reported an increased likelihood of re-infarction (HR, 1.66; 
95% CI 1.03-2.69) among patients that discontinued statins, β-blockers or calcium channel 
blockers after and AMI.  A patient was classified as non-persistent if the refill gap exceeded 
three times the day supply of the previous prescription. 
There have been very few studies (Ho et al., 2008; Levy et al., 2004) that have measured 
adherence to secondary prevention therapies as a time-varying predictor while estimating its 
association with cardiovascular outcomes or all-cause mortality.  Ho et al. (2008) computed 
adherence to statins, ACEIs, and β-blockers for each 180-day interval among patients with 
Coronary Artery Disease (CAD), identified using the Kaiser Permanente of Colorado’s database.  
The median follow-up was 4.1 years.  Non-adherence to each of the 3 classes of drugs was found 
to be common and remained significantly associated with higher risk of all-cause mortality, 
cardiovascular mortality, cardiovascular hospitalization, and revascularization procedures.  Cox 
proportional hazards models with a time-varying covariate for medication non-adherence was 
used for analysis.  Using a similar analytic model and a time-dependent measure of β-blocker 
use, the risk of dying during periods of β-blocker use was found to be attenuated (HR, 0.6; 95% 
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CI 0.5 to 0.7) when compared to the risk of dying when the drug was not available (Levy et al., 
2004).  The authors operationalized drug exposure by creating a drug-by-day matrix where β-
blocker use for each day for each subject was represented by a binary variable.   
Delaney et al. (2009) compared the estimates for the effect of β-blocker use post-AMI on 
all-cause mortality over a 9 month follow-up period from a marginal structural model (MSM) 
and traditional regression model.  Patients’ blood pressure was used as the time varying 
confounder and β-blocker use post AMI was defined as the presence of at least 1 β-blocker 
prescription in the 90days post-AMI.  A protective effect of post-AMI β-blocker use was found 
using both models.  The estimate from the MSM however, was found to be closer to that derived 
from a meta-analysis of RCTs, while that from the traditional model overestimated the 
effectiveness.  
Marginal Structural Models (MSMs) 
MSMs were proposed around a decade ago (Robins, 1999; Robins et al. 2000) to account for 
time-dependent confounding.  Some studies that have employed this technique have reported 
differences in estimates with MSMs and those obtained by traditional methods (Hernan, et al., 
2000; Bodnar, et al., 2004; Teng et al., 2005; Cole, et al., 2005).  They all recommend the use of 
MSMs in the presence of time-dependent confounding.   
 Hernan et al. (2000) used MSMs to estimate the causal effect of zidovudine on the 
survival of human immune-deficiency virus (HIV) positive men.  CD4 lymphocyte count was 
modeled as the time-dependent confounder.  After controlling for baseline covariates, the 
standard survival analysis methods yielded a decrease in the mortality rate ratio to 1.7 (95% CI 
1.4 to 1.9) from a crude estimate of 2.3 (95% CI 2.0 to 2.7).  However, on using MSMs to 
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account for time-dependent confounding the mortality rate ratio was found to be 0.7. (95% CI 
0.6 to 0.9).  Bodnar et al. (2004) describe the application of MSMs to estimate the causal effect 
of iron supplementation during pregnancy on the odds of anemia at delivery.  On accounting for 
time-dependent confounding they observed a reduction in the odds of anemia by 93% associated 
with the treatment, whereas, ordinary logistic regression models suggested a 4.3 fold increase in 
the odds.  Similarly, the 2-year survival benefit associated with injectable vitamin D among 
hemodialysis patients was found to be 20% using Cox proportional hazard analysis with time-
varying treatment, and 26% using MSMs.  Yu et al. (2010) estimated the effects of medication 
adherence to hypoglycemics on the risk of micro vascular complications in type 2 diabetes 
patients.  The Cox models with time-invariant and time-varying adherence measures, and after 
accounting for time-varying covariates, presented a detrimental effect of higher adherence.  The 
estimates from MSM, however, suggested that higher medication adherence may results in a 
reduced risk of micro vascular complications among patients with type 2 diabetes. 
 The estimates of the effect of physical activity on COPD development obtained using 
MSMs and standard approaches were not found to be different (Garcia-Aymerich, Lange, Serra, 
Schnohr, & Anto, 2008).  The authors conclude that time-dependent confounding may have not 
played a significant role in this relationship.  They also suggest that publication bias could be 
another issue, as studies that do not find differences between standard methods and MSMs 
probably do not get published.  It is important to make a note of this issue.  However, they also 
acknowledge the fact that they may have misspecified the model. 
 Considering the above, this study aims to explore the differences between estimates 
obtained from several traditional methods and MSMs using the same study population.  As 
mentioned earlier, it is very likely that studies that do not show benefits of the MSM 
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methodology over conventional methods do not get published.  In addition to the model 
specification, previous studies have also taken varied approaches as far as the measurement of 
adherence is concerned while estimating the effect of adherence on outcomes.       
Measuring Medication Adherence 
The terms adherence, compliance and persistence are commonly used and often inappropriately 
interchanged.  On conducting a comprehensive literature review the Medication and Compliance 
Special Interest Group of ISPOR, the International Society for Pharmacoeconomics and 
Outcomes Research (Cramer et al., 2007) proposed two different and distinct concepts to use 
while studying medication behavior.  Adherence to (or compliance with) a medication regimen 
was defined as the ‘extent to which a patient acts in accordance with the prescribed interval and 
dose of a dosing regimen’.  There is a subtle difference between the two terms ‘adherence’ and 
‘compliance’.  The term ‘compliance’ suggests that the patient is passively following the 
doctor’s orders and is not involved in shared decision-making with the physician as far as his/her 
therapeutic regimen is concerned (Osterberg, & Blaschke, 2005).  However, when measured 
using observational data, they are essentially synonymous.  Medication ‘persistence’ was defined 
as ‘the duration of time from initiation to discontinuation of therapy’ (Cramer et al., 2007). 
 There are many different methods of assessing medication adherence.  These have been 
broadly categorized as direct and indirect (Osterberg, & Blaschke, 2005).  As suggested by 
Osterberg, and Blaschke (2005) direct methods involve direct observation and/or directly 
measuring the level of the drug, metabolite or biological marker in the blood stream after 
administration.  Although these methods are considered more robust, they have a few limitations, 
the most significant of which is that they are neither practical nor economical.  Indirect methods 
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of measuring adherence include but are not limited to self-reports, pill counts, questionnaires, 
electronic medication monitors, patients diaries, and use of pharmacy claims data (Ellis, 
Shumaker, Sieber, & Rand, 2000; Osterberg, & Blaschke, 2005; Vermiere et al. 2001).  Each of 
these methods has their own drawbacks and advantages. 
 The use of pharmacy claims data to measure adherence is widespread and has been 
associated with a broad range of outcomes in various different medical conditions (Ho et al., 
2008; Simpson et al., 2006).  Several measures of adherence using pharmacy data have been 
proposed over the years.  Hess, Raebel, Conner, & Malone (2006) compared 11 of these 
measures: Continuous Measure of Medication Acquisition (CMA), Continuous Multiple Interval 
Measure of Oversupply (CMOS), Medication Possession Ratio (MPR), Medication Refill 
Adherence (MRA), Continuous Measure of Medication Gaps (CMG), Continuous Single Interval 
Measure of Medication Acquisition (CSA), Proportion of Days Covered (PDC), Refill 
Compliance Rate (RCR), Medication Possession Ratio, modified (MPRm), Dates Between Fills 
Adherence Rate (DBR), and Compliance Rate (CR).  The two most commonly used adherence 
measures in observational studies include MPR and PDC (Ho, Bryson, & Rumsfeld, 2009; 
Martin et al., 2009).  MPR is essentially defined by dividing the total days supply for the 
considered medication(s) during a set period of time by the pre-defined period of time (Steiner, 
& Prochazka, 1997).  It has been consistently used to study medication adherence patterns and 
has been reported as one of the best predictors of subsequent outcomes for simple drug users 
(Hess et al., 2006; Karve, & Martin, 2007; Karve et al., 2008).  A variation in the measurement 
of MPR is seen across studies with some researchers using the last refill while computing the 
numerator (Andrade, Kahler, Frech, & Chan, 2006; Hamilton, & Briceland, 1992), whereas 
others exclude it (Andrade et al., 2006; Bramley, Gerbino, Nightingale, & Frech-Tamas, 2006).  
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It has been used as a continuous variable or categorical variable (≥ 80% high, 40%-79% 
medium, < 40% low) (Andrade et al. 2006; Bramley et al., 2006; Hamilton, & Briceland, 1992; 
Rasmussen et al., 2007).  PDC has been conceptualized as the proportion of days the patient has 
the medication over a pre-defined interval of time (Benner et al., 2002).  It is indicative of days 
of overlap as well as gaps in therapy as the method to compute it requires each day of medication 
coverage to be flagged using a binary indicator.  The resulting proportion is similar to MPR; 
however, it can be different when computing compliance for a class of medications where 
individuals take multiple drugs from the same class, simultaneously.  Simply summing up the 
days supply while using MPR, will overestimate the adherence for that class of drugs (Martin et 
al., 2009).  Using multiple drugs from the same class, simultaneously, would not lead to an 
increase in the drug count using PDC.  Thus, the main difference between these 2 measures is 
that although the PDC varies between 0 and 1, the MPR can be ≥1 (Andrade et al., 2006; Hess et 
al. 2006; Ho et al., 2009; Steiner, & Prochazka, 1997); however, it is often truncated to 1 
(Cantrell, Eady, Shah, Regan, & Sokol, 2006; Keene, Eady, Nelson, & Sarnes, 2005).  Even 
while measuring adherence over shorter intervals of time using one adherence measure over 
another may make a difference.  Using MPR in such scenarios will overestimate the adherence 
during one period of time, say 3 months, and underestimate it in the consecutive 3 month 
window if the patient pre-fills his/her claim before the start of the second 3 month period.   
Three other alternatives that have been proposed in the same group of measures are 
MEDSUM, MEDOUT (Steiner, Koepsell, Fihn, & Inui, 1988) and ReComp (Bryson, Au, 
Young, McDonnell, & Fihn, 2007).  MEDSUM is essentially the same as MPR and is calculated 
as (quantity of pills dispensed)/(pills per dose × doses per day)/(days in interval).  MEDOUT 
represents the proportion of days the patient does not have the drug available.  Refill Compliance 
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(ReComp) is a validated algorithm recently proposed by Bryson et al. (2007) and has been 
shown to be better suited when adherence is measured over shorter observation intervals 
repeatedly.  In their analysis, ReComp yielded a better R
2
 than MEDOUT and MEDSUM for 
shorter intervals, in all three different medication adherence-outcomes models.  The measure is 
computed in a manner similar to PDC, however, over supply from previous periods is accounted 
for, which is not the case with PDC (Martin et al., 2009).  The ReComp measure has been used 
successfully in other studies since it was initially proposed (Lambert-Kerzner et al., 2012; 
Thorpe, Bryson, Maciejewski, & Bosworth, 2009; Wang, Liu, Bryson, Sharp, & Maciejewski, 
2011).  The details of computing ReComp have been elaborated upon in the methods section. 
Specific Aims and Hypotheses 
In order to meet the specific aims listed previously, this study tested the following sets of 
hypotheses based on the literature: 
Aim 1: To explore the predictors of patient adherence to secondary prevention therapies 
post-AMI. 
H1a: Age, gender, ethnicity, geographic region, Charlson comorbidity index (CCI), length of 
hospital stay, type of surgical procedure, other comorbid conditions and concomitant therapy are 
predictors of adherence to statin therapy post-AMI. 
H1b: Age, gender, ethnicity, geographic region, CCI, length of hospital stay, type of surgical 
procedure, other comorbid conditions and concomitant therapy are predictors of adherence to β-
blocker therapy post-AMI. 
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H1c: Age, gender, ethnicity, geographic region, CCI, length of hospital stay, type of surgical 
procedure, other comorbid conditions and concomitant therapy are predictors of adherence to 
angiotensin converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker (ARB) therapy 
post-AMI.  
Aim 2: To explore the relationship between adherence to secondary prevention therapies 
post-AMI measured as a time-invariant variable and the risk of subsequent outcomes. 
H2a: Patients that are more adherent to statin therapy post-AMI measured as a time-invariant 
predictor, are at a lower risk of suffering a i) recurrent AMI and ii) mortality compared to those 
who are less adherent, after adjusting for additional covariates. 
H2b: Patients that are more adherent to β-blocker therapy post-AMI measured as a time-invariant 
predictor, are at a lower risk of suffering a i) recurrent AMI and ii) mortality compared to those 
who are less adherent, after adjusting for additional covariates. 
H2c: Patients that are more adherent to ACEI/ARB therapy post-AMI measured as a time-
invariant predictor, are at a lower risk of suffering a i) recurrent AMI and ii) mortality compared 
to those who are less adherent, after adjusting for additional covariates. 
Aim 3: To explore the relationship between adherence to secondary prevention therapies 
post-AMI measured as a time-varying variable and the risk of subsequent outcomes. 
H3a: Patients that are more adherent to statin therapy post-AMI measured as a time-varying 
predictor, are at a lower risk of suffering a i) recurrent AMI and ii) mortality compared to those 
who are less adherent, after adjusting for additional covariates. 
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H3b: Patients that are more adherent to β-blocker therapy post-AMI measured as a time-varying 
predictor, are at a lower risk of suffering a i) recurrent AMI and ii) mortality compared to those 
who are less adherent, after adjusting for additional covariates. 
H3c: Patients that are more adherent to ACEI/ARB therapy post-AMI measured as a time-varying 
predictor, are at a lower risk of suffering a i) recurrent AMI and ii) mortality compared to those 
who are less adherent, after adjusting for additional covariates. 
Aim 4: To compare predictive values of adherence measured as a time-varying and time-
invariant variable in assessing the risk of subsequent outcomes. 
H4a: The time-varying measure of adherence to statin therapy post-AMI is superior to the time-
invariant measure in predicting subsequent outcomes, after adjusting for additional covariates. 
H4b: The time-varying measure of adherence to β-blocker therapy post-AMI is superior to the 
time-invariant measure in predicting subsequent outcomes, after adjusting for additional 
covariates. 
H4c: The time-varying measure of adherence to ACEI/ARB therapy post-AMI is superior to the 
time-invariant measure in predicting subsequent outcomes, after adjusting for additional 
covariates. 
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CHAPTER 3 
METHODOLOGY 
The broad purpose of this study was to explore the effect of long-term adherence to 
secondary prevention therapies post-AMI on subsequent cardiovascular events using time-
constant and time-varying measures of adherence.  To achieve this, a longitudinal cohort 
observational study design was employed using the retrospective Medicare 5% random national 
sample claims data from January 1
st
, 2006 to December 31
st, 
2008.  Data for the study were 
obtained from the Centers for Medicare and Medicaid Services (CMS) via a Data Use 
Agreement (DUA) outlining the specifics of the study protocol.  Additionally, the study was 
approved by the Institutional Review Board (IRB) at The University of Mississippi.  
Data Source 
Medicare is a national social program, administered by the U.S. federal government since 1965. 
It provides access to health insurance coverage for elderly U.S. citizens aged 65 years and older, 
as well as younger individuals with disabilities and end stage renal disease (ESRD).  The 
program has four parts.  Part A covers hospital care, Part B covers outpatient medical services, 
and Part D covers outpatient prescription drugs.  Medicare Advantage, also known as Medicare 
Part C is another option provided by the federal government for beneficiaries to receive their Part 
A and B benefits through private health insurance, and hence is also known as Medicare + 
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Choice plan.  A 5 % random national sample of the Medicare claims data is available for 
research purposes through the CMS and was used for analysis purposes. 
 The following Research Identifiable Files (RIFs) for 2006-2008 were requested; the 
Master Beneficiary Summary File, the Carrier RIF, the Outpatient RIF, the MedPAR RIF, and 
the Part D Drug Event (PDE) File.  The Master Beneficiary Summary File includes person-level 
data and comprises of several segments.  Of these, the Medicare Enrollment segment contains 
data on the beneficiaries’ enrollment status, demographics, and managed care and part D 
enrollment indicators.  The Carrier RIF also known as the Physician/Supplier Part B claims file 
includes claim-level information from non-institutional providers i.e. physicians, physician 
assistants, nurse practitioners, and so on.  The file contains data on diagnosis and procedure 
codes, dates of service, reimbursement amounts, and provider numbers.  The Outpatient RIF 
contains claim-level data similar to the Carrier file, except the claims submitted are from 
institutional outpatient providers such as hospital outpatient departments, rural health clinics, 
renal dialysis facilities, outpatient rehabilitation facilities, community mental health centers and 
so on.  Each record on the MedPAR RIF represents an inpatient hospital or skilled nursing 
facility (SNF) stay and may represent multiple claims from the beneficiary’s stay for that event.  
The variables in the dataset are similar to the ones in the Carrier and Outpatient files.  The PDE 
data contains prescription claim information such as National Drug Codes (NDCs), days supply, 
date of service, and drug costs.  The records in these files can be linked to each other using the 
encrypted beneficiary identification code, which allows one to identify and analyze health care 
utilization data for a particular beneficiary over several years (http://www.resdac.org/cms-
data/file-family/Medicare-Claims). 
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Rationale for use of Medicare 5% random national sample data.  The Medicare 5% data was 
found to be appropriate for analysis purposes due to several reasons.  Firstly, the algorithm that 
was used to identify patients with an initial episode of AMI was validated using Medicare data 
and reported to have a 94.1% (95% CI, 93.0% - 95.2%) predictive validity (Kiyota et al., 2004).  
The authors conclude that discharge diagnosis codes in Medicare claims data for AMI are highly 
accurate and suitable for use in epidemiologic studies.  Identification of the target population 
accurately is a key question in any claims-based study and this reduces the error due to 
misclassification greatly.  Additionally, the data has a nationally representative sample which 
extends the generalizability of the results.  A possible limitation of using the data could be that 
the study population comprised of elderly individuals ≥65 years of age.  According to Heart 
Disease and Stroke Statistics-2012 update the average age at first AMI is 64.5 years for men and 
70.3 years for women (Roger et al., 2012); therefore studying this population can be justified.  
However, the association between adherence and outcomes in this population may not be 
representative of a younger population, and hence results should be interpreted cautiously.  The 
statistics also report that among patients aged ≥65 years at initial AMI approximately 25% have 
a recurrent MI within 5 years and ≈28% die within a year.  This implies that with a sufficiently 
large sample size the frequency of event occurrence should be sufficient for statistical techniques 
that have been used later on.  A major drawback was the unavailability of data on certain crucial 
risk factors, such as smoking.  However, this information is not available in most claims data that 
would be required for the study purpose.  
Study Design and Study Population 
The Medicare 5% random national sample files from January 1, 2006 through December 31, 
2008 were analyzed (Figure II).  Service claims from July 1, 2006 through June 30, 2007 were 
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used to identify patients with an initial episode of AMI using an identification algorithm 
validated by Kiyota et al. (2004).  As per the algorithm, a hospitalization episode lasting at least 
3 days and ≤180 days with an International Classification of Diseases, Ninth Revision, Clinical 
Figure II Graphical representation of study design 
 Modification (ICD-9-CM) diagnosis code of 410.x1 (x = 0 to 9) in the primary or secondary 
diagnosis position was used to identify an episode of AMI.  The date of discharge following the 
initial hospitalization episode of AMI was used as the index date for subjects.  Re-admission 
within 8 weeks for a subsequent episode of care related to the initial AMI has an ICD-9-CM 
diagnosis code of 410.x2 and an old episode of AMI has an ICD-9-CM diagnosis code of 412.xx.  
Therefore, patients with an ICD-9-CM diagnosis code of 410.x2 or 412.xx listed as any of the 
diagnoses codes for a hospitalization episode that occured before the index date were excluded 
from the study.  Further, occasionally, in some claims related to a hospitalization episode due to 
AMI the fifth digit in the ICD-9-CM diagnosis code is populated as zero (i.e. 410.x0), which 
represents an unspecified episode of care.  These patients were included in the study and their 
medical claim records before the index date were analyzed to ensure the inclusion of only those 
Jan 1, 2006 
Jul 1, 2006 
Jun 30, 2007 
Dec 31, 2008 
Minimum follow-up of 18 months Pre-identification period 
Identification Window 
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with an initial episode of care.  It is precisely for this reason that the study design includes a pre-
index period from January 1, 2006 to June 30, 2006.  This pre-identification period was used to 
analyze the claims history of patients included in the study earlier on during the identification 
window and to gain information on baseline comorbidities (elaborated upon later).  Similarly, the 
study design allows for a minimum 18 month follow-up period (upto December 31, 2008) after 
the identification window to ensure sufficient time to study the adherence-outcome relationship 
among patients with an index date towards the end of the identification window.  Studies have 
shown that adherence to treatment starts declining after 2 years (Akincigil et al., 2007).   
After identification of initial AMI episodes, only patients that did not have a recurrent 
AMI for the first 90 days and survived the first 90 days were included in the study.  These 
patients probably have a more severe disease burden and have other factors associated with the 
outcome, such as use of drug post discharge rather than adherence.  Since the objective of the 
study is to determine the association between long-term adherence and outcomes, this exclusion 
criterion is justified.  Selected beneficiaries were required to have continuous enrollment in 
Medicare Parts A, B, & D, from 6 months before to 12 months after the index date, or up until 
their death date if they died within a year.  Continuous enrollment 6 month prior to the index 
date was required to obtain prior medication history.  Continuous enrollment 12 months after the 
index date enabled acquiring sufficient adherence data before the subject was censored.  
Continuous enrollment throughout the study period was not opted for as it may lead to a 
reduction in sample size.  Instead, censoring patients at the end of 12 months post the index date 
in case of disenrollment led to additional data points that were used for the analysis.  Further, 
patients enrolled in Medicare due to disabilities and/or ESRD were excluded, and those with 
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claims for SNF during the study period were excluded as their prescription claims may not be 
present.  
Following their inclusion as described above, AMI patients that initiated statin therapy 
within 90 days post-discharge were included in cohort A.  Similarly, those that initiated β-
blocker therapy within 90 days post-discharge were included in cohort B.  However, β-blockers 
are contraindicated in patients with asthma (Smith et al., 2011; Himmelstein, Woolhandler, 
Hellander, & Wolfe, 1999); therefore subjects that filled a prescription for inhaled corticosteroids 
or had an asthma diagnosis in their claims in the previous 6 months were excluded from cohort 
B.  Additionally, patients with hypotension, sinus bradycardia and partial AV block (see 
Appendix A, Table XIX for ICD-9-CM diagnosis and procedure codes) were also excluded from 
this cohort using diagnosis codes from previous claims.  Further, chronic obstructive pulmonary 
disease and insulin-dependent diabetes mellitus are relative rather than absolute 
contraindications, patients with these conditions were not excluded, but these conditions were 
controlled for.  Finally, patients that initiated ACEI/ARB therapy within 90 days post-discharge 
constituted cohort C.  NDC codes were used to identify prescription drug claims to create the 3 
cohorts (refer to Appendix B for list of drugs that were considered).  Sample attrition details are 
provided in Table I. 
The selected patient cohort was followed until the first occurrence of any one of the 
following events: 1) disenrollment from Medicare Parts A, B, or D, 2) occurrence of the 
outcome, and 3) the end of the study period (31
st
 December, 2008).  
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Table I Sample Attrition 
  Inclusion/exclusion criteria N 
1 Subjects with Initial AMI between Jul 1, 2006 and Jun 30, 2007 identified 
using a valid algorithm 
15,840 
2 Excluding subjects enrolled due to ESRD and/or other disabilities 13,753 
3 Excluding subjects with HMO coverage at any time during study period 12,569 
4 Subjects with continuous enrollment in Medicare parts A/B and D 6 months 
prior and 12 months post index date or up to death date (whichever comes 
first) 
5,445 
5 Excluding subjects with skilled nursing facility (SNF) claims any time during 
the study period 
2,933 
6 Excluding subjects with previous AMI claims 2,555 
7 Excluding subjects that died within 90 days of hospital discharge 1,698 
8 Excluding subjects with a recurrent MI in the first 90 days post discharge 1,549 
9a Patients that initiated statin therapy within 90 days post-discharge (cohort A) 1,091 
9b Patients that initiated β-blocker therapy within 90 days post-discharge (cohort 
B) 
1,021 
9c Patients that initiated ACEI/ARB therapy within 90 days post-discharge 
(cohort A) 
1,025 
 
Adherence Measurement 
For each class of drugs the ReComp measure was used to compute adherence over 1 year as a 
time-constant measure and over 90-day intervals as time-varying.  If a patient died within the 
interval, adherence beginning the first day of the interval to the death date was computed.  The 
algorithm for the measure has been validated and recommended for use while measuring 
adherence over short intervals of time, repeatedly (Bryson et al., 2007).  Hence, it was preferred 
for use in this study. 
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Figure III Graphical illustration of a prescription refill pattern 
 
Consider a patient with prescription claim history as illustrated in Figure III above.  The 
adherence measure for the first 90-day interval will be computed as ([30+30+10])/90 i.e. 0.78.  If 
one would use the MPR measure and sum the days supply within the specified interval, the 
adherence would be 1.  On using the PDC, the adherence for the first 90-day interval would be 
computed as 0.78, which is similar to the ReComp measure.  However, oversupply is not 
accounted for while computing the PDC (Martin et al., 2009) and hence the difference would 
arise in the second 90-day interval.  Here the PDC measure would be ([30+20]/90) i.e. 0.56.  
Taking into account the additional 20 days where the patient had the medication due to pre-fill in 
the previous 90 day interval, the ReComp measure of adherence would be 0.78.   
Briefly, the MPR would overestimate the adherence in some intervals, while 
underestimating it in others.  The PDC would underestimate adherence in intervals following a 
pre-fill in the previous one.  Thus, the ReComp was found to be best suited for this study design. 
01/05 – 02/05 
02/20 – 03/20 
03/10 – 04/10 
04/25 – 05/25 
06/10 – 07/10 
6/20 – 7/20 
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Study Variables 
Adherence.  Adherence to statins, β-blockers and ACEI/ARBS was computed as described 
above.  The time-varying measure was computed over each 90 day interval, beginning the index 
date, and up until the last date the subject was still in the study as per the study design.  A 90-day 
interval was considered suitable as certain refills are for a 90 day supply, thus, shorter intervals 
would not work.  Time periods greater than 90 days would not capture the truly dynamic nature 
of adherence.  The time-constant measure was computed over a 1-year period post-index date.  
While computing adherence to a particular class of medications, say statins, medication 
switching from one drug to another in the same class of drugs was not classified as 
discontinuation of drug therapy.  Consequently, patients who switch from ACEIs to ARBs or 
vice versa were considered as still continuing therapy.  The adherence level over the period 
under consideration was dichotomized using the 80% value.  Thus, subjects with an adherence of 
≥80% were considered adherent for that particular period and those below 80% were classified 
as non-adherent.  Although the dichotomous cutoff is arbitrary, it has been used for a majority of 
the studies on medication adherence in the literature (Claxton, Cramer & Pierce, 2001; DiMatteo 
et al., 2002; DiMatteo, 2004).  The 80% cutoff may be too low for certain classes of medications 
such as oral contraceptives or human immunodeficiency virus; however, it seems reasonable for 
cardiovascular medications (Bryson et al., 2007; Ho et al., 2009).  A dichotomous variable was 
preferred over a continuous measure due to the ease of interpretation of the final hazard ratios the 
former offers over the latter.  Additionally, sensitivity analyses with various cutoff points 
between 40% and 90% were also conducted to substantiate the conclusion. 
Baseline covariates.  Socio-demographic variables such as age, gender, ethnicity, and region of 
U.S. were included as baseline covariates.  These have been shown to be predictors of adherence 
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among varied classes of chronic medications in numerous studies (Gislason et al., 2006; Gislason 
et al., 2007; Rasmussen et al., 2007).  Age in years at the index date was categorized as 65-70 
years, 71-75 years, 76-80 years, 81-85 years, and 85+ years.  Gender was classified into male 
and female.  Ethnicity was categorized as White, Black, and other.  Regions of the U.S. was 
grouped into Northeast, Midwest, South and West as per the United States Census Bureau 
(http://www.census.gov/geo/www/us_regdiv.pdf) using the state codes in the demographic file.  
The Charlson Comorbidity Index (CCI) measured over the 6-month pre-index period was used as 
an indicator of the baseline clinical condition of the patient (D’Hoore, Bouckaert, & Tilquin, 
1996).  The length of hospital stay classified as <7 days and ≥7 days was used as a measure of 
the severity of the patient’s condition.  If the patient received percutaneous coronary intervention 
(PCI) during the hospital stay it was indicated using a dichotomous variable.  Similarly, an 
indication of treatment with coronary artery bypass graft (CABG) surgery during hospital stay 
was used as a baseline covariate (see Appendix A, Table XIX for ICD-9-CM procedure codes).  
The presence of angina and coronary artery disease, as dichotomous variables, prior to the initial 
AMI hospitalization were also computed.  In addition to these, in patients on β-blocker therapy 
(cohort B) prior COPD was controlled for (see Appendix A, Table XIX for ICD-9-CM diagnosis 
codes).  Dichotomous variables were also used to indicate prior use of statin, β-blocker, and 
ACEI/ARB therapy, respectively. 
Time-varying confounders.  The time-varying confounders were measured over each 90-day 
interval, beginning the index date, till the last day of follow-up for each subject.  Number of 
office/outpatient visits was measured as a count variable.  Any hospitalization visit and any ER 
visit were accounted for as dichotomous variables.  Presence of revascularization procedures 
such as PCI and CABG were accounted for dichotomously.  The presence of any diagnosis 
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related to conditions recognized as risk factors for secondary AMI were controlled for.  These 
include hypertension, diabetes, dyslipidemia, congestive heart failure, cerebrovascular disease, 
and peripheral vascular disease (see Appendix A, Table XIX for ICD-9-CM diagnosis codes).  In 
addition to these, another variable indicated the presence of any diagnosis related conditions that 
have a very low survival rate.  These included chronic kidney disease and cancer.  The number 
of drugs with unique active ingredients in every 90-day interval was also computed.  Additional 
HMO coverage and Medicare Part D donut hole status for every quarter was controlled for.  
Total out-of-pocket Medicare cost for enrollees for every quarter was also included as a time-
varying predictor. 
 In addition to the above time-varying confounders, for cohort A, where the effect of long-
term adherence to statins on outcomes was investigated, adherence to β-blockers and adherence 
to ACEI/ARBs was also included as time-varying confounders.  Similarly, when adherence to β-
blockers or adherence to ACE/ARBs is the primary variable of interest, adherence to the other 
two classes under consideration was included as a time-varying confounder.  However, in cases 
where the individual is not taking one or both of the other drug classes, the adherence was not 
zero, but rather indicated as ‘drug not taken’.  Therefore, when adherence was modeled as a 
time-varying confounder it was not a dichotomous variable, but had three levels representing 
adherence ≥80%, <80% and absence of drug, respectively. 
 Finally, in analysis models where the outcome variable is time to mortality the 
occurrence of subsequent AMI episodes was included as a dichotomous time-varying covariate. 
Outcomes.  Two outcome variables were studied.  The first outcome was defined as time from 
the index date to the occurrence of the first episode of a recurrent AMI.  Similarly, the time to 
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mortality from the index date was the second outcome.  Time in this case will be measured in 
discrete intervals (90 days) or continuously (daily) depending on the statistical model used.  This 
has been elaborated upon later. 
Data Analysis  
The data management and the data analysis for the study were conducted using Statistical 
Analysis Software (SAS) version 9.3.  The baseline descriptive characteristics for all subjects 
have been reported using means and standard deviations for continuous variables, and number 
and percentages for categorical variables.  Additional descriptives of the data such as the average 
and median quarters of follow up as well as the average number of subjects adherent to each 
class of drug during each quarter have been provided.  The data analysis plan for each of the 
specific aims is discussed below. 
Aim 1: To explore the predictors of patient adherence to secondary prevention therapies 
post-AMI. 
To examine predictors of adherence to statin therapy, multivariable logistic regression models 
were used.  The time-invariant, dichotomous, 1-year adherence measure was used as the 
dependent variable with all the baseline covariates included in the model.  Similar, multivariable 
logistic regression models were used to examine predictors of adherence to β-blocker therapy 
and ACEI/ARB therapy. 
Aim 2: To explore the relationship between adherence to secondary prevention therapies 
post-AMI measured as a time-invariant variable and the risk of subsequent outcomes. 
The Cox proportional hazard models (Cox, 1972) were used to estimate the effect of adherence 
on the risk of subsequent outcomes.  The model provides a semi-parametric regression technique 
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to estimate the risk associated with the occurrence of events at specific intervals of time due to 
certain factors.  The basic model is usually represented as, 
  ( )     ( )   (                   )………………………………………………......(1) 
which suggests that the hazard for an individual i at time t is a product of the baseline hazard 
function and the exponentiated linear function of a set of k covariates.  Around 10-20 variables 
per event have been suggested for the generation of accurate estimates (Concato et al., 1995; 
Peduzzi, Concato, Feinstein, & Holford, 1995).   
 The model was estimated using the time-invariant dichotomous measure of adherence to 
statins (using cohort A) as the primary predictor variable with time to recurrent AMI and time to 
mortality as the dependent variable, respectively.  Baseline covariates were adjusted for.  
Additionally, the presence of concomitant therapy with β-blockers and ACEI/ARBs were also 
adjusted for.   
 Similar analyses were conducted using adherence to β-blocker (using cohort B) and 
ACEI/ARB (using cohort C) therapy as primary variables of interest, respectively. 
Aim 3: To explore the relationship between adherence to secondary prevention therapies 
post-AMI measured as a time-varying variable and the risk of subsequent outcomes. 
In order to achieve the above purpose, 3 different modeling strategies were constructed with 
varying specifications.  Model 1 included the baseline covariates and time-varying adherence.  
Model 2 included the baseline covariates, time-varying covariates and time-varying adherence; 
however, the dynamic interactions between the covariates and adherence measures are ignored in 
this model.  Lastly Model 3 was a MSM which included the baseline covariates, time-varying 
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covariates and time-varying adherence and also accounted for the effect of time-dependent 
confounding.  All of the above models were used to generate estimates of the effects of 
adherence to each of the 3 drug classes under consideration on each of the 2 outcomes discussed 
earlier. 
Discrete-event time models (models 1 and 2).  In this case the time dependent covariates were 
measured at regular intervals of 90 days i.e. quarterly which do not correspond to the units in 
which the event times were measured i.e. days.  A Cox proportional hazard model with time-
varying predictors cannot be directly used with this data.  Singer and Willet (2003) have 
suggested 3 ways of dealing with this situation: 1) to impute predicted values for the 
intermediate event times, 2) to disregard time-varying predictors completely, and 3) to round the 
event times so as to reflect the time-intervals over which the predictors are measured.  Option 1 
does not seem feasible as the study includes several time-dependent variables for a large sample 
size and their values will be required to be imputed for each day of follow up.  Disregarding the 
time-varying predictors would mean ignoring valuable information, thus option 2 was not opted 
for
1
.  Therefore, the occurrence of the event i.e. recurrent AMI or mortality over the 90-day 
interval was used as the outcome variable. 
 Now, since the occurrence of the event is being measured at discrete intervals (quarterly) 
rather than continuously (daily), Cox’s model for discrete-event time data, with a complementary 
log-log (clog-log) link, was used for analysis (model 1 and model 2).  The model is represented 
as follows: 
                                                          
1
 Prior studies (Ho et al., 2008; Levy et al., 2004; Yu et al. 2010) that have measured adherence as a time-
varying variable have used continuous time models to estimate the effect of adherence on outcomes. 
Therefore in order to be able to compare our results, findings from continuous time models (models 1b 
and 2b) have also been reported in Appendix C – Additional Results. 
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           (   )   [                         ]   
                              …………………(2) 
 On the right side of equation 2, the first set of parameters, as a group, represent the baseline 
clog-log hazard function i.e. the value of the clog-log hazard when all the P substantive 
predictors are 0.  The second set, as a group, represents the shift in the baseline clog-log hazard 
function corresponding to unit changes in the predictors.  If one of the predictors, say X2 was 
time-varying, then individual i’s value of clog-log hazard in time j depends on his value of X1, 
X3,… XP, which is time-invariant, and his value of X2 in time j. 
 The left-side of equation 2 uses a clog-log transformation. It yields the logarithm of the 
negated logarithm of the probability of event non-occurrence. 
            (     (             )……………………………………………….……(3) 
 The advantage of using a clog-log transformation over a logit transformation is that with 
the former the model invokes a proportional hazards assumption like the Cox proportional 
hazards model and not a proportional odds assumption as is the case with the latter (Singer & 
Willet, 2003; Allison, 2010).  The benefit of this is that the β coefficients in the discrete-event 
time data are estimating the same underlying parameters as those estimated by the coefficients in 
the Cox proportional hazards model, and hence can be directly compared.  The coefficients 
obtained have a relative hazard interpretation just like those from the Cox proportional hazards 
model.  Additionally, it makes the model invariant to the time interval length i.e. months, years.  
The clog-log transformation has been recommended for use over the logit transformation in 
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cases where the underlying metric for time is truly continuous but discrete intervals are observed 
only due to other difficulties (measurement-related or design-related).  
 There are two issues that may arise with the addition of time-varying predictors that 
deserve mention: state and rate dependence, which are types of reverse causation (Singer & 
Willet, 2003).  State dependence occurs when the value of a time-varying predictor in a 
particular interval is affected by the occurrence of the event earlier on in the same interval.  
Similarly, if the time-varying predictors’ value is affected by the individual’s value of hazard in 
the same period then rate-dependence is said to have occurred.  For example, if the patient has 
suffered a recurrent AMI within the first 10 days of the quarter, his/her adherence over the latter 
part of the observation period may be affected by this.  The suggested method to reduce 
ambiguity would be to lag the values of the covariates by one observation period (i.e. a quarter) 
(Singer & Willet, 2003; Allison, 2010).  This would require the deletion of cases that had the 
event occurrence during the first quarter.  However, since such cases are not included in the 
study population (based on the exclusion criteria); the lagged values of the time-varying 
predictors were used. 
MSMs (model 3).  Lastly, as mentioned above, model 3 was a MSM that aims to estimate the 
effects of long-term adherence to each of the 3 classes of drugs on each of the 2 outcomes under 
consideration, by accounting for the effects of time-dependent confounders. 
 It is important to understand the concept of counterfactuals (Rothman & Greenland, 
1998; Hernan, Brumback, & Robins, 2002) to appreciate the utility of MSMs.  Let A(t) be a 
dichotomous variable that represents exposure at time t.  Therefore, at the end of each 
observation period (quarter, in our case) it can either be 0 or 1.  If the study consists of K 
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observation periods, then there will be 2
K
 different possible values for Ā(K), where Ā represents 
exposure history.  Let YĀ represent the observed outcome for a subject with exposure history Ā.  
Only one value of the outcome can be observed for each subject as they have a unique exposure 
history.  All the other outcomes are called counterfactuals.  Therefore for a subject an exposure is 
said to have a causal effect on outcome if YĀ(t)≠YĀ’(t) for exposure history Ā and Ā’.  On a 
population level, there is a causal relationship if the mean outcome for a particular exposure 
history is not equivalent to the mean outcome for a different exposure history.  Therefore for 
each Ā, a MSM model can be specified as, 
   ( | )     ( )       ( )       …………………………………………………………(4) 
where     ( | ) is the hazard of death at time t among subjects with baseline covariates X, had 
they all followed treatment history Ā.  β1 and β2 are the parameters to be estimated and    is the 
baseline hazard function.  
  The model is fitted in a two-stage process.  First, the probability of each subject having 
his/her own treatment history is estimated which is then used to derive inverse-probability-of-
treatment weights (IPTWs).  Second, these weights are then used while estimating the 
adherence-outcome association via a regression model. 
 The IPTWs, in practice tend to be non-normally distributed and highly variable.  
Therefore the use of stabilized weights has been recommended (Hernan et al., 2000; 2002), due 
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to the smaller variance and narrower 95% CI intervals obtained
2
.  These are derived using the 
following equation, 
  ( )   ∏
   ( )| ̅(   )  
   ( )| ̅(   )  ̅( ) 
 
   …………………………………………………….(5) 
 where A(k) represents the treatment at time k and Ā(k-1) represents the prior treatment history, V 
represents the baseline covariates, and  ̅( ) represents the time-varying covariates through time 
k inclusive of the baseline covariates.  Essentially, the numerator can be thought of as the 
conditional probability of a subject receiving his/her own observed treatment at time k, given the 
prior treatment history and baseline covariates.  Similarly, the denominator represents the 
conditional probability of a subject receiving his/her own observed treatment at time k, given the 
prior treatment history and prognostic factors (it accounts for the predictive effect of the time-
varying covariates).  To estimate the IPTW, separate logistic regression models were used for the 
numerator and the denominator (see Faries & Kadziola, 2012 for SAS codes; see Fewell et al. 
2004 for STATA commands), with adherence being the dependent variable in both.  Estimation 
of the numerator included the baseline covariates as independent variables, whereas estimation 
of the denominator included time-varying covariates too. 
 To account for subject drop-out before the end of the study period, the inverse-probability 
of-censoring weight was estimated in a similar fashion as the IPTW above.  The stabilized 
version of this weight is, 
   ( )   ∏
   ( )  | ̅(   )   ̅(   )      
   ( )  | ̅(   )   ̅(   )  ̅(   )     
 
   …………………………………...(6) 
                                                          
2
 MSMs using normalized stabilized weights (Xiao, Abrahamowicz, & Moodie, 2010) were also fitted 
to the data as the variability of the stabilized weights was not found to be optimum. The results of MSMs 
using normalized stabilized weights are reported in Appendix C – Additional Results. 
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where C(t) represents if the subject is censored, taking the value 1 when censored at time t and 0 
when not and  ̅( ) denotes the censoring history.  Therefore, the numerator can be thought of as 
the conditional probability of the subject not being censored at time k, given his prior censoring 
and treatment history inclusive of baseline covariates.  The denominator is essentially the same, 
other than the fact that it incorporates the time-varying predictors.  The estimation of the 
censoring weights was carried out in a similar fashion as that of the treatment weights.  Logistic 
regression was used to estimate the numerator and the denominator (see Faries & Kadziola, 2012 
for SAS codes; see Fewell et al. 2004 for STATA commands).  A binary flag indicating whether 
the subject was censored was used as the dependent variable. 
 On accounting for censoring, the equation for the estimation of the stabilized IPTWs 
changes to  
  ( )   ∏
   ( )| ̅(   )   ( )   
   ( )| ̅(   )  ̅( )  ( )   
 
   ……………………………………………...….(7) 
However, this does not make any difference while computing the weights. 
 The final weight for each subject’s observation is a product of the IPTWs and censoring 
weights, given as 
  ( )     ( )………………………………………………………………………………..(8) 
To implement the final MSM a Cox proportional hazard model was used with each 
person-quarter as an observation for weighting.  Lagged observations were used.  Additionally, 
weighing introduces within subject correlation, therefore, robust sandwich variance estimators 
were derived (see Faries & Kadziola, 2012 for SAS codes; see Fewell et al. 2004 for STATA 
commands).   
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The MSMs provide consistent estimates of the causal inference based on three 
assumptions: 1) no unmeasured confounders, 2) there exists a positive probability for each 
treatment for each set of covariates and 3) specification of the correct models to estimate the 
weights and carry out the analysis.  Several methods to study the sensitivity of the MSM to the 
presence of unmeasured confounding have been suggested (Robins, 1999; Brumback, Hernan, 
Haneuse, & Robins, 2004).  One of the methods suggested is to measure the amount of such 
confounding through a sensitivity parameter, called alpha and confounding function.  It stands 
for a measure of how different the potential outcomes are for patients in different treatment 
groups.  Faries & Kadziola, 2012 provide a detailed method for computation of alpha using SAS.   
Similarly, the positivity assumption can be assessed by estimating the probability of being 
adherent using all possible covariates across all observation periods (Mortimer, Neugebauer, van 
der Laan & Tager, 2005).  However, this is beyond the scope of this study and will be followed 
up in subsequent research. 
Aim 4: To compare predictive values of adherence measured as a time-varying and time-
invariant variable in assessing the risk of subsequent outcomes. 
Four models have been specified so far, a Cox proportional hazard model with adherence as 
time-invariant predictor, two discrete-event time models, one with and one without time-varying 
predictors and lastly a MSM (not including the continuous time models).  The estimates of the 
association between long-term adherence and outcomes obtained from each of these was 
compared against each other and to the estimates obtained from previous randomized controlled 
trials and observational studies.   
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Model that are nested (discrete-event time models 1 & 2) can be compared using the 
deviance statistic (-2 log likelihood current model ).  When a series of models are fit to the same data, 
the smaller the deviance statistic, the better the fit of the model (Singer & Willett, 2003).     
 The relative-goodness of fit of models that are not nested within each other can be 
compared using the Akaike Information Criterion (AIC) and the Bayesian Information Criterion 
(BIC) as long as they are fit to the same data (Singer & Willett, 2003).  The model with the 
smaller AIC and/or BIC is the one with the better fit.  The general consensus for the BIC is that a 
difference of 0 to 2 points suggests a weak improvement, 2 to 6 – positive, 6 to 10 – strong, and 
> 10 very strong.  However, it should be kept in mind that these are just guidelines and it is not 
an exact science.  The various goodness-of-fit statistics for all the models have been reported. 
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CHAPTER 4 
RESULTS 
Baseline Sample Characteristics 
As discussed in the methods section, a total of 1,427 patients were included in the study after 
applying the inclusion and exclusion criteria.  Of the 1,427 patients, cohort A (statin therapy) 
comprised of 1,091 patients, and cohorts B (β-blocker therapy) and C (ACEI/ARB therapy) 
included 1,021 and 1,025 patients, respectively, based on their prescription records.  Table II 
presents the socio-demographic and other baseline characteristics of all 1,427 subjects, as well as 
the distribution of the characteristics across all three study cohorts.  The 1,427 patients were 
approximately equally distributed across the age groups: 65-70 years (20.32%), 71-75 years 
(22.56%), 76-80 years (21.65%), 81-85 years (16.75%), and >85 years (18.71%).  A majority of 
the patients were female (61.53%), White (84.72%), and resided in the Southern region of the 
U.S. (44.50%).  The average CCI score of the sample was 6.67 (±3.41).  For a majority of the 
patients the length of hospital stay associated with the initial episode of AMI was less than 7 
days (68.40%) and a minority had either a CABG (11.42%) or a PCI (36.23%) procedure 
performed during that stay.  As far as prior history is concerned, 11.49% of the total sample had 
been diagnosed with Angina and 45.20% had prior CAD.  Almost half of the patients were 
already on statin (44.36%), β-blocker (47.37%) or ACEI/ARB therapy (52.07%) before the 
initial AMI episode.  The socio-demographic and baseline characteristic distribution across 
cohorts A, B, and C was similar to that of the total sample (Table II). 
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Table II Baseline sample characteristics 
    Cohort A  Cohort B Cohort C 
 All Subjects (Statin 
Therapy) 
(β-blocker 
therapy) 
(ACEI/ARB 
Therapy) 
  N (1,427) N (1,091) N (1,021) N (1,025) 
Age, n (%)          
65 - 70 years 290 20.32 237 21.72 221 21.65 207 20.20 
71 - 75 years 322 22.56 263 24.11 232 22.72 251 24.49 
76 - 80 years 309 21.65 223 20.44 225 22.04 213 20.78 
81 - 85 years 239 16.75 187 17.14 162 15.87 170 16.59 
> 85 years 267 18.71 181 16.59 181 17.73 184 17.95 
Gender, n (%)          
Male 549 38.47 433 39.69 396 38.79 378 36.88 
Female 878 61.53 658 60.31 625 61.21 647 63.12 
Ethnicity, n (%)          
White 1,209 84.72 924 84.69 875 85.7 869 84.78 
Black 124 8.69 92 8.43 85 8.33 87 8.49 
Other 94 6.59 75 6.87 61 5.97 69 6.73 
Region of US, n (%)          
Northeast 218 15.28 176 16.13 154 15.08 162 15.80 
Midwest 385 26.98 299 27.41 284 27.82 272 26.54 
South 635 44.50 456 41.80 446 43.68 454 44.29 
West 189 13.24 160 14.67 137 13.42 137 13.37 
CCI, mean (SD) 6.67 3.41 6.62 3.44 6.36 3.26 6.68 3.44 
Length of Hospital Stay, n (%)          
< 7 days 976 68.40 748 68.56 705 69.05 714 69.66 
≥ 7 days 451 31.60 343 31.44 316 30.95 311 30.34 
Surgical Procedure, n (%)          
CABG 163 11.42 140 12.83 131 12.83 99 9.66 
PCI 517 36.23 425 38.96 401 39.28 402 39.22 
Prior Angina, n (%)  164 11.49 123 11.27 94 9.21 110 10.73 
Prior CAD, n (%)  645 45.20 488 44.73 405 39.67 460 44.88 
Prior Therapy, n (%)         
Prior Statin Therapy 633 44.36 553 50.69 427 41.82 453 44.20 
Prior β-blocker Therapy 676 47.37 512 46.93 480 47.01 497 48.49 
Prior ACEI/ARB Therapy 743 52.07 548 50.23 507 49.66 619 60.39 
Concurrent Therapy, n (%)          
Concurrent Statin Therapy 1,091 76.45 ─ ─ 770 75.42 775 75.61 
Concurrent β-blocker Therapy  1,021 71.55 770 70.58 ─ ─ 724 70.63 
Concurrent ACEI/ARB Therapy 1,025 71.83 775 71.04 724 70.91 ─ ─ 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, 
Charlson comorbidity index; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft; CAD, coronary artery disease 
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Aim 1: Predictors of Time-invariant Adherence 
Based on the time-invariant 1 year adherence measure, 60.71% of the patients in cohort A were 
adherent to statin therapy, when a measure of ≥0.8 was defined as adherent (see Chapter 3, 
Methods for a detail description of how adherence was computed).  Similarly, 61.39% of the 
patients in cohort B and 56.05% of the patients in cohort C were adherent to β-blocker and 
ACEI/ARB therapy, respectively.  Table III presents predictors of the time-invariant 1 year 
adherence measure in cohorts A, B, and C, respectively.   
Age emerged as a significant predictor of adherence to current β-blocker therapy.  The 
odds of being adherent were higher for patients in the 76-80 year old (Odds Ratio (OR) = 1.75; 
95% CI [1.14, 2.69]; p < 0.0104) and 81-85 year old (OR = 1.86; 95% CI [1.67, 2.97]; p = 
0.0092) age groups, when compared to >85 year old patients.  Males (OR = 0.68; 95% CI [0.51, 
0.90]; p < 0.0072) were also less likely to be adherent to their β-blocker therapy when compared 
to females.  White patients had significantly higher odds of being adherent to statin therapy (OR 
= 1.62; 95% CI [1.02, 2.56]; p = 0.0407), when compared to Black patients.   Among cohort B 
patients, those residing in the Northeast had higher odds of being adherent, when compared to 
their counterparts in the South (OR = 1.70; 95% CI [1.17, 2.59]; p < 0.0134).   
Prior therapy also emerged as a significant predictor of adherence across all three cohorts. 
Patients on prior statin therapy were more likely to adhere to their current statin therapy when 
compared to patients not on prior statin therapy (OR = 1.89; 95% CI [1.41, 2.53]; p < .0001).  
Similarly, patients on prior ACEI/ARB therapy were more likely to adhere to their current statin 
therapy when compared to patients not on prior ACEI/ARB therapy (OR = 1.37; 95% CI [1.02, 
1.83]; p < 0.0356).  Patients on prior β-blocker therapy were more likely to adhere to
49 
 
Table III Predictors of time-invariant adherence 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  OR 95% CI p OR 95% CI p OR 95% CI p 
Age          
65 - 70 years 0.79 [0.50, 1.23] 0.2960 1.41 [0.92, 2.18] 0.1184 0.94 [0.59, 1.49] 0.7933 
71 - 75 years 0.82 [0.53, 1.27] 0.3732 1.39 [0.90, 2.14] 0.1335 1.43 [0.92, 2.24] 0.1168 
76 - 80 years 0.76 [0.49, 1.19] 0.2366 1.75 [1.14, 2.69] 0.0104* 1.10 [0.70, 1.73] 0.6737 
81 - 85 years 0.69 [0.44, 1.09] 0.1082 1.86 [1.67, 2.97] 0.0092* 1.10 [0.69, 1.76] 0.6945 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.10 [0.83, 1.45] 0.5078 0.68 [0.51, 0.90] 0.0072* 0.91 [0.68, 1.22] 0.5140 
Female Ref   Ref   Ref   
Ethnicity          
White 1.62 [1.02, 2.56] 0.0407* 1.56 [0.97, 2.51] 0.0663 1.01 [0.60, 1.70] 0.9767 
Other 1.44 [0.73, 2.82 0.2903 1.08 [0.53, 2.17] 0.8386 0.81 [0.39, 1.68] 0.5658 
Black Ref   Ref   Ref   
Region of US          
Northeast 1.28 [0.86, 1.89] 0.2197 1.70 [1.17, 2.59] 0.0134* 1.12 [0.74, 1.70] 0.5834 
Midwest 1.27 [0.92, 1.76] 0.1500 1.37 [0.99, 1.91] 0.0567 1.18 [0.84, 1.67] 0.3380 
West 0.98 [0.65, 1.47] 0.9195 0.92 [0.61, 1.38] 0.6719 0.91 [0.59, 1.41] 0.6743 
South Ref         
CCI 0.99 [0.95, 1.03] 0.6515 1.01 [0.96, 1.05] 0.7320 0.96 [0.92, 1.00] 0.0694 
Length of Hospital Stay          
< 7 days 1.05 [0.76, 1.50] 0.7527 1.00 [0.72, 1.38] 0.9837 0.91 [0.65, 1.27] 0.5824 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 1.56 [0.96, 2.54] 0.0712 1.31 [0.81, 2.12] 0.2653 1.03 [0.61, 1.76] 0.9034 
PCI 1.31 [0.97, 1.78] 0.0822 1.18 [0.87, 1.61] 0.2847 1.27 [0.92, 1.74] 0.1422 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  OR 95% CI p OR 95% CI p OR 95% CI p 
Prior Angina 0.94 [0.61, 1.44] 0.7697 1.49 [0.89, 2.50] 0.1313 1.13 [0.70, 1.81] 0.6234 
Prior CAD 0.78 [0.58, 1.06] 0.1117 0.83 [0.61, 1.13] 0.2345 0.81 [0.59, 1.11] 0.1914 
Prior Therapy             
Prior Statin Therapy, 1.89 [1.41, 2.53] <.0001* 1.15 [0.86, 1.55] 0.3524 1.20 [0.88, 1.63] 0.2408 
Prior β-blocker Therapy 0.96 [0.72, 1.28] 0.7930 1.54 [1.14, 2.08] 0.0054* 1.01 [0.75, 1.38] 0.9363 
Prior ACEI/ARB Therapy 1.37 [1.02, 1.83] 0.0356* 0.75 [0.56, 1.00] 0.0512 3.68 [2.72, 4.97] <.0001* 
Concurrent Therapy             
Concurrent Statin Therapy ─ ─ ─ 0.87 [0.63, 1.21] 0.4028 1.26 [0.91, 1.76] 0.1704 
Concurrent β-blocker Therapy 1.07 [0.80, 1.44] 0.6556 ─ ─ ─ 1.09 [0.80, 1.48] 0.6042 
Concurrent ACEI/ARB Therapy 1.13 [0.83, 1.52] 0.4377 1.13 [0.84, 1.53] 0.4286 ─ ─ ─ 
*p<0.05 
OR, Odds Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease
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their current β-blocker therapy, when compared to patients not on prior therapy (OR = 1.54; 95% 
CI [1.14, 2.08]; p < 0.0054) and the odds of being adherent to current ACEI/ARB therapy were 
significantly higher for patients on prior ACEI/ARB therapy when compared to patients not on 
prior ACEI/ARB therapy (OR = 3.68; 95% CI [2.72, 4.97]; p < .0001). 
Aim 2: Time-invariant Adherence as a Predictor of Outcomes 
Model 1: Baseline covariates and time-invariant adherence as predictors. 
Recurrent AMI.   Table IV presents the results of the Cox proportional hazards model 
estimating the effect of time-invariant adherence to statin, β-blocker, and ACEI/ARB therapy in 
cohorts A, B, and C, respectively, on the risk of a recurrent AMI.  Time-invariant adherence to 
statins was not significantly associated with the hazard of a recurrent AMI (Hazard Ratio (HR) = 
0.73; 95% CI [0.47, 1.15]; p = 0.1707); neither was adherence to β-blockers (HR = 0.95; 95% CI 
[0.59, 1.54]; p = 0.8435), nor ACEI/ARBs (HR = 0.98; 95% CI [0.61, 1.58]; p = 0.9381). 
The hazard of a recurrent AMI increased significantly with age.  This was observed 
across all three study cohorts.  Patients aged between 65-70 years (Hazard Ratio (HR) = 0.45; 
95% CI [0.23, 0.90]; p = 0.0246) and 76-80 years (HR = 0.49; 95% CI [0.25, 0.97]; p = 0.0419) 
in cohort A had a significantly lower hazard of a recurrent AMI when compared to patients >85 
year old.  Similarly, in cohorts B and C, 71-75 year olds (cohort B: HR = 0.46; 95% CI [0.22, 
0.96]; p = 0.0380, cohort C: HR = 0.47; 95% CI [0.24, 0.90]; p = 0.0227) and 76-80 year olds 
(cohort B: HR = 0.47; 95% CI [0.23, 0.97]; p = 0.0406, cohort C: HR = 0.43; 95% CI [0.21, 
0.86]; p = 0.0177) had a lower hazard of recurrent AMI, when compared to elderly patients >85 
year old.  Among Cohort A patients, those residing in the Western region of the country had a  
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Table IV Model 1: Predictors of the hazard of a recurrent AMI 
  Cohort A  
(Statin Therapy)  
Cohort B 
 (β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.45 [0.23, 0.90] 0.0246* 0.55 [0.27, 1.12] 0.0982 0.55 [0.28, 1.09] 0.0849 
71 - 75 years 0.53 [0.28, 1.00] 0.0513 0.46 [0.22, 0.96] 0.0380* 0.47 [0.24, 0.90] 0.0227* 
76 - 80 years 0.49 [0.25, 0.97] 0.0419* 0.47 [0.23, 0.97] 0.0406* 0.43 [0.21, 0.86] 0.0177* 
81 - 85 years 0.62 [0.32, 1.19] 0.1515 1.02 [0.54, 1.95] 0.9435 0.86 [0.46, 1.61] 0.6281 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.07 [0.67, 1.68] 0.7885 1.10 [0.68, 1.79] 0.7016 1.14 [0.72, 1.80] 0.5846 
Female Ref   Ref   Ref   
Ethnicity          
White 1.28 [0.60, 2.71] 0.5191 1.81 [0.71, 4.62] 0.2111 0.84 [0.43, 1.66] 0.6178 
Other 1.05 [0.33, 3.31] 0.9388 1.95 [0.54, 6.96] 0.3063 0.52 [0.16, 1.70] 0.2761 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.82 [0.46, 1.46] 0.4962 0.86 [0.45, 1.63] 0.6362 0.60 [0.32, 1.14] 0.1173 
Midwest 0.65 [0.38, 1.13] 0.1286 0.75 [0.43, 1.32] 0.3219 0.67 [0.39, 1.15] 0.1450 
West 0.38 [0.17, 0.87]  0.0216* 0.59 [0.27, 1.29] 0.1883 0.72 [0.37, 1.43] 0.3462 
South Ref   Ref   Ref   
CCI 1.09 [1.03, 1.16] 0.0050* 1.15 [1.08, 1.23] <.0001* 1.12 [1.06, 1.19] 0.0002* 
Length of Hospital Stay          
< 7 days 1.12 [0.67, 1.85] 0.6717 1.86 [1.03, 3.36] 0.0408* 1.33 [0.79, 2.24] 0.2768 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.40 [0.15, 1.08] 0.0703 0.66 [0.24, 1.81] 0.4204 0.65 [0.24, 1.73] 0.3857 
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  Cohort A  
(Statin Therapy)  
Cohort B 
 (β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.47 [0.27, 0.80] 0.0055* 0.55 [0.32, 0.94] 0.0275* 0.65 [0.40, 1.08] 0.0962 
Prior Angina 1.48 [0.83, 2.66] 0.1865 1.09 [0.54, 2.18] 0.8188 1.49 [0.84, 2.67] 0.175 
Prior CAD 1.10 [0.67, 1.82] 0.7016 0.97 [0.57, 1.60] 0.8645 1.18 [0.71, 1.94] 0.5274 
Prior Therapy          
Prior Statin Therapy, 0.86 [0.54, 1.37] 0.5224 1.12 [0.68, 1.85] 0.6492 1.17 [0.73, 1.88] 0.5096 
Prior β-blocker Therapy 1.39 [0.87, 2.22] 0.1737 1.43 [0.86, 2.38] 0.1684 1.50 [0.93, 2.42] 0.0958 
Prior ACEI/ARB Therapy 0.99 [0.61, 1.60] 0.9689 1.19 [0.72, 1.95] 0.4954 0.88 [0.53, 1.45] 0.6099 
Concurrent therapy          
Concurrent Statin Therapy ─ ─ ─ 0.82 [0.48, 1.41] 0.4715 0.94 [0.56, 1.59] 0.8203 
Concurrent β-blocker Therapy 0.98 [0.62, 1.57] 0.9449 ─ ─ ─ 1.13 [0.70, 1.81] 0.6257 
Concurrent ACEI/ARB Therapy 1.44 [0.85, 2.44] 0.1716 1.32 [0.77, 2.28] 0.3169 ─ ─ ─ 
          
TIME-CONSTANT ADHERENCE          
Statin Adherence 0.73 [0.47, 1.15] 0.1707 ─ ─ ─ ─ ─ ─ 
β-blocker Adherence ─ ─ ─ 0.95 [0.59, 1.54] 0.8435 ─ ─ ─ 
ACEI/ARB Adherence ─ ─ ─ ─ ─ ─ 0.98 [0.61, 1.58] 0.9381 
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
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significantly lower hazard of a recurrent AMI when compared to patients from the South (HR = 
0.38; 95% CI [0.17, 0.87]; p = 0.0216). 
 As far as clinical characteristics are concerned, the hazard of a recurrent AMI increased 
significantly with a patient’s CCI across all three cohorts (cohort A: HR = 1.09; 95% CI [1.03, 
1.16]; p = 0.0050, cohort B: HR = 1.15; 95% CI [1.08, 1.23]; p < .0001, cohort C: HR = 1.12; 
95% CI [1.06, 1.19]; p = 0.0002).  Among cohort B patients, those that were hospitalized for less 
than a week for their initial AMI had a higher hazard of a recurrent episode when compared to 
patients with a hospital stay ≥7 days (HR = 1.86; 95% CI [1.03, 3.36]; p = 0.0408).   Finally, a 
significantly lower hazard of a recurrent AMI was observed among patients that had a PCI 
procedure performed during their initial hospital stay when compared to patients that did not 
have the surgery performed (cohort A: HR = 0.47; 95% CI [0.27, 0.80]; p = 0.0055, cohort B: 
HR = 0.55; 95% CI [0.32, 0.94]; p = 0.0275). 
Mortality.  Table V presents the results of the Cox proportional hazards model estimating the 
effect of time-invariant adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, 
and C, respectively, on the risk of mortality.  Time-invariant adherence to statins was not 
significantly associated with the hazard of mortality (HR = 0.73; 95% CI [0.53, 1.00]; p = 
0.0531); neither was adherence to β-blockers (HR = 1.21; 95% CI [0.86, 1.71]; p = 0.2704), nor 
ACEI/ARBs (HR = 1.04; 95% CI [0.75, 1.44]; p = 0.8215).   
The hazard of death increased significantly with age across all three cohorts.  Patients 
aged between 65-70 years (cohort A: HR = 0.39; 95% CI [0.23, 0.65]; p = 0.0003, cohort B: HR 
= 0.23; 95% CI [0.13, 0.40]; p < .0001, cohort C: HR = 0.38; 95% CI [0.23, 0.62]; p = 0.0002), 
71-75 years (cohort A: HR = 0.41; 95% CI [0.26, 0.67]; p = 0.0003, cohort B: HR = 0.27; 95% 
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CI [0.16, 0.46]; p < .0001, cohort C: HR = 0.35; 95% CI [0.22, 0.56]; p < .0001), 76-80 years 
(cohort A: HR = 0.47; 95% CI [0.29, 0.76]; p = 0.0021, cohort B: HR = 0.27; 95% CI [0.17, 
0.44]; p < .0001, cohort C: HR = 0.42; 95% CI [0.27, 0.64]; p < .0001), and 81-85 years (cohort 
A: HR = 0.64; 95% CI [0.41, 0.99]; p = 0.0475, cohort B: HR = 0.59; 95% CI [0.38, 0.90]; p = 
0.0153) had a lower hazard of death, when compared to elderly patients >85 years old. 
 Among clinical characteristics, the hazard of death increased significantly with a patient’s 
CCI across all three cohorts (cohort A: HR = 1.14; 95% CI [1.09, 1.19]; p < .0001, cohort B: HR 
= 1.16; 95% CI [1.10, 1.21]; p < .0001, cohort C: HR = 1.13; 95% CI [1.08, 1.18]; p < .0001).  
Patients that had a CABG surgery performed during their initial hospital stay had a significantly 
lower hazard of death (cohort A: HR = 0.25; 95% CI [0.11, 0.55]; p = 0.0006, cohort B: HR = 
0.39; 95% CI [0.18, 0.84]; p = 0.0154, cohort C: HR = 0.28; 95% CI [0.12, 0.64]; p = 0.0029), 
when compared to patients that did not have the surgery.  Similar results were obtained for a PCI 
procedure (cohort A: HR = 0.29; 95% CI [0.18, 0.46]; p < .0001, cohort B: HR = 0.31; 95% CI 
[0.19, 0.49]; p < .0001, cohort C: HR = 0.33; 95% CI [0.22, 0.51]; p < .0001), whereby patients 
that had the procedure performed were less likely to die than those that did have the procedure 
performed. 
Patients that were on ACEI/ARB therapy prior to the initial AMI episode had a 
significantly higher hazard of death (HR = 1.74; 95% CI [1.20, 2.52]; p = 0.0035), when 
compared to patients with no prior history of ACEI/ARB therapy among cohort C patients.  
Additionally, among cohort B and C patients, those that were on concomitant statin therapy 
reported a significantly lower hazard of death, in comparison to patients that were not on 
concomitant statin therapy (cohort B: HR = 0.61; 95% CI [0.43, 0.86]; p = 0.0056, cohort C: HR 
= 0.63; 95% CI [0.46, 0.88]; p = 0.0058).
56 
 
Table V Model 1: Predictors of the hazard of death 
  Cohort A  
(Statin Therapy)  
Cohort B 
 (β-blocker Therapy)  
Cohort C 
 (ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.39 [0.23, 0.65] 0.0003* 0.23 [0.13, 0.40] <.0001* 0.38 [0.23, 0.62] 0.0002* 
71 - 75 years 0.41 [0.26, 0.67] 0.0003* 0.27 [0.16, 0.46] <.0001* 0.35 [0.22, 0.56] <.0001* 
76 - 80 years 0.47 [0.29, 0.76] 0.0021* 0.27 [0.17, 0.44] <.0001* 0.42 [0.27, 0.64] <.0001* 
81 - 85 years 0.64 [0.41, 0.99] 0.0475* 0.59 [0.38, 0.90] 0.0153* 0.72 [0.48, 1.08] 0.1145 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.25 [0.90, 1.74] 0.1803 1.41 [1.00, 1.99] 0.0491 1.15 [0.84, 1.59] 0.3822 
Female Ref   Ref   Ref   
Ethnicity          
White 0.95 [0.59, 1.55] 0.8484 1.09 [0.63, 1.88] 0.7639 0.81 [0.52, 1.28] 0.3685 
Other 1.00 [0.49, 2.04] 0.9898 0.90 [0.40, 2.06] 0.8063 0.60 [0.29, 1.23] 0.1596 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.76 [0.49, 1.18] 0.2232 0.76 [0.48, 1.20] 0.2362 0.66 [0.43, 1.01] 0.0561 
Midwest 0.95 [0.64, 1.41] 0.8124 0.72 [0.48, 1.07] 0.1067 0.75 [0.51, 1.09] 0.1320 
West 0.67 [0.40, 1.12] 0.1248 0.59 [0.33, 1.04] 0.0665 0.79 [0.49, 1.27] 0.3303 
South Ref   Ref   Ref   
CCI 1.14 [1.09, 1.19] <.0001* 1.16 [1.10, 1.21] <.0001* 1.13 [1.08, 1.18] <.0001* 
Length of Hospital Stay          
< 7 days 0.93 [0.66, 1.31] 0.6650 0.99 [0.69, 1.41] 0.9368 0.81 [0.59, 1.10] 0.1739 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.25 [0.11, 0.55] 0.0006* 0.39 [0.18, 0.84] 0.0154* 0.28 [0.12, 0.64] 0.0029* 
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  Cohort A  
(Statin Therapy)  
Cohort B 
 (β-blocker Therapy)  
Cohort C 
 (ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.29 [0.18, 0.46] <.0001* 0.31 [0.19, 0.49] <.0001* 0.33 [0.22, 0.51] <.0001* 
Prior Angina 1.04 [0.66, 1.66] 0.8593 0.63 [0.36, 1.11] 0.1128 1.07 [0.68, 1.69] 0.7618 
Prior CAD 0.98 [0.68, 1.40] 0.9116 1.21 [0.85, 1.73] 0.2848 1.11 [0.80, 1.55] 0.5233 
Prior Therapy          
Prior Statin Therapy, 0.97 [0.69, 1.37] 0.8718 1.13 [0.79, 1.62] 0.5015 0.91 [0.66, 1.26] 0.5775 
Prior β-blocker Therapy 0.81 [0.59, 1.13] 0.2248 1.08 [0.77, 1.53] 0.6638 0.77 [0.56, 1.04] 0.0890 
Prior ACEI/ARB Therapy 1.34 [0.94, 1.91] 0.1043 1.24 [0.88, 1.77] 0.2241 1.74 [1.20, 2.52] 0.0035* 
Concurrent therapy          
Concurrent Statin Therapy ─ ─ ─ 0.61 [0.43, 0.86] 0.0056* 0.63 [0.46, 0.88] 0.0058* 
Concurrent β-blocker Therapy 0.91 [0.65, 1.26] 0.5675 ─ ─ ─ 0.91 [0.67, 1.24] 0.5621 
Concurrent ACEI/ARB Therapy 1.13 [0.79, 1.63] 0.5107 1.13 [0.78, 1.62] 0.5204 ─ ─ ─ 
 
            
TIME-CONSTANT ADHERENCE          
Statin Adherence 0.73 [0.53, 1.00] 0.0531 ─ ─ ─ ─ ─ ─ 
β-blocker Adherence ─ ─ ─ 1.21 [0.86, 1.71] 0.2704 ─ ─ ─ 
ACEI/ARB Adherence ─ ─ ─ ─ ─ ─ 1.04 [0.75, 1.44] 0.8215 
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
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Time-varying Confounders 
The total study cohort comprising of 1,427 subjects were followed for an average 7.64 and 
median 8 quarters (Table VI).  They contributed to a total of 10,904 person-quarter observations.  
Patients in cohorts A, B, and C contributed to a total of 8,497, 7,920, and 7,832 person-quarters, 
respectively.  Table VII (a and b) presents the descriptives of the time-varying confounders over 
the observed time-period for all study subjects. (Refer to Appendix C – Additional Results, 
Tables XX, XXI, and XXII for descriptive statistics of time-varying confounders over the 
observed quarters for cohorts A, B, and C, respectively.) 
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Table VI Quarters observed 
   Quarters Observed 
N Mean SD Median Mode Min Max Range 
All  Subjects 1,427 7.64 2.01 8 8 1 11 10 
Cohort A (Statin Therapy) 1,091 7.79 1.87 8 8 2 11 9 
Cohort B (β-blocker Therapy)  1,021 7.76 1.94 8 8 1 11 10 
Cohort C (ACEI/ARB Therapy) 1,025 7.64 2.02 8 8 2 11 9 
SD, standard deviation; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker 
Table VIIa Time-varying confounders for all subjects 
 Quarters Observed 
 1 2 3 4 5 6 
  N = 1,427 N = 1,426 N = 1,371 N = 1,322 N = 1,282 N = 1,241 
No. of office/outpatient visits, 
mean (SD) 
16.57 13.90 11.87 12.01 10.32 10.50 9.74 10.63 9.85 11.49 9.24 9.99 
Hospitalization visit (any 
cause), n (%) 
199 13.95 119 8.35 92 6.71 61 4.61 70 5.46 56 4.51 
Emergency room visit (any 
cause), n (%) 
244 17.10 172 12.06 131 9.56 121 9.15 115 8.97 102 8.22 
Receipt of PCI and/or 
CABG, n (%) 
64 4.48 20 1.40 13 0.95 7 0.53 14 1.09 14 1.13 
Presence of claim related to 
risk factors, n (%) 
1,252 87.74 1,105 77.49 1,017 74.18 956 72.31 910 70.98 897 72.28 
Presence of claim related to 
low-survival rate conditions, 
n (%) 
254 17.80 230 16.13 203 14.81 170 12.86 182 14.20 179 14.42 
No. of unique prescription 
claims, mean (SD) 
9.91 4.07 8.15 4.01 7.82 4.01 7.88 4.06 7.69 3.95 7.59 3.9 
Part D coverage gap, n (%) 427 29.92 507 35.55 590 43.03 527 39.86 447 34.87 403 32.47 
Out of pocket Medicare 
costs, mean (SD) 
520.63 653.46 534.13 666.47 517.22 828.59 475.26 577.83 471.13 1011.24 439.22 598.76 
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 Quarters Observed 
 1 2 3 4 5 6 
  N = 1,427 N = 1,426 N = 1,371 N = 1,322 N = 1,282 N = 1,241 
Recurrent AMI, n (%) ─ ─ 30 2.10 18 1.31 20 1.51 24 1.87 15 1.21 
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial 
infarction 
Table VIIb Time-varying confounders for all subjects 
 Quarters Observed 
 7 8 9 10 11 
  N = 1,217 N = 871 N = 507 N = 229 N = 11 
Number of office/outpatient 
visits, mean (SD) 
8.6 10.25 7.75 12.96 7.19 10.97 4.79 6.93 0.27 0.47 
Hospitalization visit (any 
cause), n (%) 
58 4.77 42 4.82 12 2.37 5 2.18 0 0.00 
Emergency room visit (any 
cause), n (%) 
97 7.97 54 6.20 25 4.93 10 4.37 0 0.00 
Receipt of PCI and/or CABG, 
n (%) 
12 0.99 7 0.80 1 0.20 2 0.87 0 0.00 
Presence of claim related to 
risk factors, n (%) 
773 63.52 517 59.36 280 55.23 105 45.85 1 9.09 
Presence of claim related to 
low-survival rate conditions, n 
(%) 
164 13.48 115 13.20 55 10.85 15 6.55 0 0.00 
Number of unique prescription 
claims, mean (SD) 
7.04 4.17 6.63 4.17 6.44 3.99 5.47 4.25 1.36 1.69 
Part D coverage gap, n (%) 401 32.95 339 38.92 226 44.58 100 43.67 6 54.55 
Out of pocket Medicare costs, 
mean (SD) 
383.34 553.49 329.28 554.35 310.76 479.68 197.19 369.42 18.83 31.24 
Recurrent AMI, n (%) 16 1.31 10 1.15 3 0.59 2 0.87 0 0.00 
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial 
infarction 
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Aim 3: Time-varying Adherence as a Predictor of Outcomes 
Model 2: Baseline covariates and time-varying adherence as predictors. 
Recurrent AMI.   Table VIII presents the results of a discrete-event time model estimating the 
effect of time-varying adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, 
and C, respectively, on the risk of a recurrent AMI.  Time-varying statin adherence was 
associated with a lower hazard of a recurrent AMI (HR = 0.63; 95% CI [0.40, 0.99]; p = 0.0471) 
among cohort A patients.  Time-varying adherence to β-blockers was not significantly associated 
with the hazard of a recurrent AMI (HR = 1.12; 95% CI [0.67, 1.89]; p = 0.6622); neither was 
adherence to ACEI/ARBs (HR = 1.57; 95% CI [0.93, 2.67]; p = 0.0931).  
The hazard of a recurrent AMI increased significantly with age.  Patients aged between 
65-70 years (cohort A: HR = 0.50; 95% CI [0.25, 0.99]; p = 0.0480), 71-75 years (cohort C: HR 
= 0.48; 95% CI [0.25, 0.93]; p = 0.0302), 76-80 years (cohort C: HR = 0.43; 95% CI [0.21, 
0.88]; p = 0.0199) had a lower hazard of a recurrent AMI, when compared to elderly patients 
>85 years old.  Among patients in cohort A, those residing in the Western region of the country 
had a significantly lower hazard of a recurrent AMI (HR = 0.40; 95% CI [0.18, 0.90]; p = 
0.0261], when compared to patients from the South. 
 The hazard of a recurrent AMI increased significantly with an increase in the CCI across 
all three cohorts (cohort A: HR = 1.09; 95% CI [1.02, 1.16]; p = 0.0067, cohort B: HR = 1.13; 
95% CI [1.06, 1.21]; p = 0.0002, cohort C: HR = 1.12; 95% CI [1.05, 1.18]; p = 0.0003).  Among 
cohort B patients, a <7 day hospitalization for the initial AMI was associated with a higher 
hazard of a recurrent episode, in comparison to a week or longer hospital stay (HR = 1.82; 95% 
CI [1.01, 3.29]; p = 0.0472).  Additionally, patients that underwent a PCI procedure during their 
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Table VIII Model 2: Predictors of the hazard of a recurrent AMI 
  Cohort A  
(Statin Therapy)  
Cohort B 
 (β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.50 [0.25, 0.99] 0.0480* 0.60 [0.29, 1.22] 0.1578 0.59 [0.30, 1.17] 0.1293 
71 - 75 years 0.56 [0.30, 1.06] 0.0734 0.49 [0.23, 1.03] 0.0596 0.48 [0.25, 0.93] 0.0302* 
76 - 80 years 0.52 [0.26, 1.02] 0.0570 0.50 [0.25, 1.02] 0.0580 0.43 [0.21, 0.88] 0.0199* 
81 - 85 years 0.66 [0.35, 1.26] 0.2096 1.04 [0.55, 1.98] 0.9048 0.87 [0.46, 1.62] 0.6500 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.06 [0.67, 1.68] 0.8092 1.09 [0.67, 1.78] 0.7288 1.16 [0.73, 1.83] 0.5371 
Female Ref   Ref   Ref   
Ethnicity          
White 1.25 [0.59, 2.66] 0.5575 1.77 [0.70, 4.50] 0.2294 0.85 [0.43, 1.69] 0.6480 
Other 1.03 [0.33, 3.26] 0.9607 1.90 [0.53, 6.81] 0.3214 0.52 [0.16, 1.72] 0.2859 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.81 [0.46, 1.45] 0.4835 0.87 [0.46, 1.65] 0.6794 0.63 [0.33, 1.20] 0.1588 
Midwest 0.65 [0.38, 1.13] 0.1285 0.75 [0.43, 1.32] 0.3236 0.67 [0.39, 1.15] 0.1481 
West 0.40 [0.18, 0.90] 0.0261* 0.61 [0.28, 1.33] 0.2135 0.73 [0.37, 1.46] 0.3783 
South Ref   Ref   Ref   
CCI 1.09 [1.02, 1.16] 0.0067* 1.13 [1.06, 1.21] 0.0002* 1.12 [1.05, 1.18] 0.0003* 
Length of Hospital Stay          
< 7 days 1.12 [0.68, 1.86] 0.6575 1.82 [1.01, 3.29] 0.0472* 1.35 [0.80, 2.27] 0.2598 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.42 [0.16, 1.12] 0.0840 0.69 [0.25, 1.88] 0.4625 0.67 [0.25, 1.79] 0.4189 
6
2
 
 
63 
 
  Cohort A  
(Statin Therapy)  
Cohort B 
 (β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.48 [0.28, 0.83] 0.0078* 0.59 [0.34, 1.01] 0.0536 0.68 [0.41, 1.12] 0.1281 
Prior Angina 1.50 [0.84, 2.69] 0.1724 1.16 [0.58, 2.32] 0.6660 1.50 [0.84, 2.68] 0.1679 
Prior CAD 1.11 [0.68, 1.83] 0.6750 0.93 [0.56, 1.56] 0.7861 1.18 [0.72, 1.94] 0.5165 
Prior Therapy          
Prior Statin Therapy, 0.85 [0.53, 1.36] 0.4948 1.12 [0.68, 1.84] 0.6547 1.20 [0.75, 1.92] 0.4556 
Prior β-blocker Therapy 1.37 [0.85, 2.20] 0.1926 1.40 [0.84, 2.33] 0.1958 1.49 [0.92, 2.40] 0.1044 
Prior ACEI/ARB Therapy 0.95 [0.68, 1.55] 0.8220 1.21 [0.72, 2.02] 0.4742 0.80 [0.49, 1.30] 0.3643 
             
TIME-VARYING ADHERENCE             
Statin Therapy          
Adherent 0.63 [0.40, 0.99] 0.0471* 0.64 [0.36, 1.12] 0.1146 0.62 [0.36, 1.05] 0.0747 
Not on therapy ─ ─ ─ 0.87 [0.46, 1.64] 0.6704 0.75 [0.41, 1.39] 0.3624 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy          
Adherent 1.18 [0.64, 2.18] 0.5933 1.12 [0.67, 1.89] 0.6622 0.98 [0.55, 1.76] 0.9466 
Not on therapy 1.14 [0.61, 2.16] 0.6811 ─ ─ ─ 0.89 [0.48, 1.67] 0.7199 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.27 [0.71, 2.27] 0.4294 1.19 [0.64, 2.20] 0.5821 1.57 [0.93, 2.67] 0.0931 
Not on therapy 0.82 [0.43, 1.54] 0.5299 0.85 [0.44, 1.67] 0.6452 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
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hospitalization associated with the initial AMI episode had a lower hazard of a recurrent AMI, 
when compared to patients that had no such procedure performed (HR = 0.48; 95% CI [0.28, 
0.83]; p = 0.0078]. 
Mortality.  The hazard ratios from a discrete-event time model estimating the effect of time-
varying adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, and C, 
respectively, on the risk of death are presented in Table IX.  Time-varying adherence to statins 
was not significantly associated with the hazard of mortality (HR = 0.86; 95% CI [0.61, 1.21]; p 
= 0.3913); neither was time-varying adherence to β-blockers (HR = 0.97; 95% CI [0.68, 1.38]; p 
= 0.8469), nor ACEI/ARBs (HR = 1.04; 95% CI [0.74, 1.46]; p = 0.8189). 
The hazard of death increased significantly with age across all three cohorts.  Patients 
aged between 65-70 years (cohort A: HR = 0.42; 95% CI [0.25, 0.70]; p = 0.0008, cohort B: HR 
= 0.25; 95% CI [0.14, 0.43]; p < .0001, cohort C: HR = 0.41; 95% CI [0.24, 0.67]; p = 0.0005), 
71-75 years (cohort A: HR = 0.43; 95% CI [0.27, 0.70]; p = 0.0006, cohort B: HR = 0.29; 95% 
CI [0.17, 0.48]; p < .0001, cohort C: HR = 0.37; 95% CI [0.24, 0.59]; p < .0001), 76-80 years 
(cohort A: HR = 0.50; 95% CI [0.31, 0.81]; p = 0.0045, cohort B: HR = 0.30; 95% CI [0.19, 
0.49]; p < .0001, cohort C: HR = 0.44; 95% CI [0.28, 0.68]; p = 0.0002), and 81-85 years (cohort 
B: HR = 0.63; 95% CI [0.41, 0.97]; p = 0.0359) had a lower hazard of death, when compared to 
elderly patients >85 years old. 
 Among clinical characteristics, the hazard of death increased significantly with a patient’s 
CCI across all three cohorts (cohort A: HR = 1.14; 95% CI [1.09, 1.19]; p < .0001, cohort B: HR 
= 1.15; 95% CI [1.09, 1.20]; p < .0001, cohort C: HR = 1.12; 95% CI [1.08, 1.17]; p < .0001).  
Patients that had a CABG surgery performed during their initial hospital stay had a significantly 
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Table IX Model 2: Predictors of the hazard of death 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.42 [0.25, 0.70] 0.0008* 0.25 [0.14, 0.43] <.0001* 0.41 [0.24, 0.67] 0.0005* 
71 - 75 years 0.43 [0.27, 0.70] 0.0006* 0.29 [0.17, 0.48] <.0001* 0.37 [0.24, 0.59] <.0001* 
76 - 80 years 0.50 [0.31, 0.81] 0.0045* 0.30 [0.19, 0.49] <.0001* 0.44 [0.28, 0.68] 0.0002* 
81 - 85 years 0.69 [0.44, 1.08] 0.1059 0.63 [0.41, 0.97] 0.0359* 0.75 [0.50, 1.13] 0.1652 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.26 [0.90, 1.75] 0.1736 1.38 [0.98, 1.95] 0.0641 1.14 [0.83, 1.58] 0.4153 
Female Ref   Ref      
Ethnicity          
White 0.94 [0.57, 1.52] 0.7868 1.08 [0.63, 1.86] 0.7796 0.84 [0.53, 1.31] 0.4347 
Other 0.96 [0.47, 1.96] 0.9042 0.95 [0.42, 2.15] 0.8971 0.62 [0.30, 1.26] 0.1864 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.76 [0.49, 1.17] 0.2116 0.79 [0.50, 1.25] 0.3090 0.69 [0.45, 1.06] 0.0885 
Midwest 0.95 [0.64, 1.41] 0.8100 0.77 [0.52, 1.15] 0.1965 0.76 [0.52, 1.11] 0.1598 
West 0.68 [0.41, 1.14] 0.1478 0.58 [0.33, 1.03] 0.0639 0.80 [0.50, 1.28] 0.3491 
South Ref   Ref   Ref   
CCI 1.14 [1.09, 1.19] <.0001* 1.15 [1.09, 1.20] <.0001* 1.12 [1.08, 1.17] <.0001* 
Length of Hospital Stay          
< 7 days 0.93 [0.66, 1.32] 0.6924 0.97 [0.68, 1.39] 0.8744 0.82 [0.60, 1.13] 0.2217 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.25 [0.11, 0.56] 0.0008* 0.39 [0.18, 0.85] 0.0169* 0.28 [0.12, 0.66] 0.0034* 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.29 [0.18, 0.46] <.0001* 0.32 [0.20, 0.50] <.0001* 0.35 [0.23, 0.53] <.0001* 
Prior Angina 1.08 [0.69, 1.71] 0.7436 0.66 [0.38, 1.16] 0.1479 1.06 [0.67, 1.67] 0.7984 
Prior CAD 1.00 [0.70, 1.43] 0.9992 1.20 [0.84, 1.71] 0.3265 1.12 [0.81, 1.57] 0.4874 
Prior Therapy          
Prior Statin Therapy, 0.94 [0.67, 1.32] 0.7212 1.10 [0.77, 1.58] 0.5932 0.90 [0.65, 1.25] 0.5368 
Prior β-blocker Therapy 0.81 [0.58, 1.13] 0.2157 1.10 [0.78, 1.56] 0.5940 0.76 [0.56, 1.04] 0.0865 
Prior ACEI/ARB Therapy 1.28 [0.89, 1.83] 0.1770 1.23 [0.86, 1.77] 0.2592 1.74 [1.20, 2.50] 0.0032* 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.86 [0.61, 1.21] 0.3913 1.07 [0.68, 1.68] 0.7766 1.06 [0.69, 1.63] 0.7806 
Not on therapy ─ ─ ─ 1.67 [1.04, 2.67] 0.0333* 1.62 [1.04, 2.52] 0.0321* 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy          
Adherent 1.02 [0.66, 1.60] 0.9206 0.97 [0.68, 1.38] 0.8469 0.91 [0.60, 1.38] 0.6524 
Not on therapy 1.11 [0.71, 1.74] 0.6397 ─ ─ ─ 1.02 [0.67, 1.54] 0.9297 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.10 [0.72, 1.69] 0.6550 1.16 [0.74, 1.82] 0.5079 1.04 [0.74, 1.46] 0.8189 
Not on therapy 0.96 [0.61, 1.52] 0.8727 0.97 [0.61, 1.54] 0.8930 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
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lower hazard of death (cohort A: HR = 0.25; 95% CI [0.11, 0.56]; p = 0.0008, cohort B: HR = 
0.39; 95% CI [0.18, 0.85]; p = 0.0169, cohort C: HR = 0.28; 95% CI [0.12, 0.66]; p = 0.0034), 
when compared to patients that did not have the surgery.  Similar results were obtained for a PCI 
procedure (cohort A: HR = 0.29; 95% CI [0.18, 0.46]; p < .0001, cohort B: HR = 0.32; 95% CI 
[0.20, 0.50]; p < .0001, cohort C: HR = 0.35; 95% CI [0.23, 0.53]; p < .0001), whereby patients 
that had the procedure performed were less likely to die than those that did not have the 
procedure performed. 
 Patients that were on ACEI/ARB therapy prior to the initial AMI episode had a 74% 
higher hazard of death (HR = 1.74; 95% CI [1.20, 2.50]; p = 0.0032), when compared to patients 
with no prior history of ACEI/ARB therapy among cohort C patients.  Additionally, among 
cohort B and C patients, those that were not on concomitant statin therapy reported a 
significantly higher hazard of death, in comparison to patients that were not adherent to 
concomitant statin therapy (cohort B: HR = 1.67; 95% CI [1.04, 2.67]; p = 0.0333, cohort C: HR 
= 1.62; 95% CI [1.04, 2.52]; p = 0.0321).  
 The results of continuous time models (model 2b) estimating the effect of time-varying 
adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, and C, respectively, on 
the risk of subsequent outcomes are presented in Appendix C – Additional Results, Tables XXIII 
and XXIV. 
Model 3: Baseline covariates, time-varying confounders and time-varying adherence as 
predictors. 
Recurrent AMI.   Table X presents the results of a discrete-event time model estimating the 
effect of time-varying adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, 
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and C, respectively, on the risk of a recurrent AMI after accounting for time-varying covariates.  
Cohort A patients that were adherent to their statin therapy had a significantly lower hazard of a 
recurrent AMI when compared to non-adherent patients (HR = 0.61; 95% CI [0.38, 0.97; p = 
0.0366).  Time-varying adherence to β-blockers was not significantly associated with the hazard 
of a recurrent AMI (HR = 1.09; 95% CI [0.65, 1.85]; p = 0.7440); neither was time-varying 
adherence to ACEI/ARBs (HR = 1.57; 95% CI [0.93, 2.68]; p = 0.8469). 
The hazard of a recurrent AMI increased significantly with age.  Patients aged between 
65-70 years (cohort A: HR = 0.48; 95% CI [0.24, 0.97]; p = 0.0397), 71-75 years (cohort C: HR 
= 0.48; 95% CI [0.25, 0.93]; p = 0.0302), 76-80 years (cohort A: 0.50; 95% CI [0.25, 0.99]; p = 
0.0470, cohort C: HR = 0.43; 95% CI [0.21, 0.88]; p = 0.0203)  had a lower hazard of a recurrent 
AMI, when compared to elderly patients >85 years old.  The hazard of a recurrent AMI for 
patients from the Western part of the country was 40% of the hazard for patients from the South 
(HR = 0.40; 95% CI [0.18, 0.91]; p = 0.0297).   
 A higher CCI was associated with an increased hazard of a recurrent AMI (cohort A: HR 
= 1.09; 95% CI [1.01, 1.16]; p = 0.0212, cohort B: HR = 1.13; 95% CI [1.05, 1.22]; p = 0.0009; 
cohort C: HR = 1.11; 95% CI [1.04, 1.19]; p = 0.0024).  Among cohort B patients, those with a 
hospital stay <7 days for the initial AMI episode reported a higher hazard of a recurrent AMI 
(HR = 1.83; 95% CI [1.01, 3.32]; p = 0.0455), when compared to patients with a week or longer 
hospital stay.  Among cohort A patients, the hazard of a recurrent AMI for those with a PCI 
procedure performed during the initial AMI hospitalization was 49% of the hazard for patients 
that did not have the procedure performed during the initial AMI hospitalization (HR = 0.49; 
95% CI [0.28, 0.84]; p = 0.0099). 
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Table X Model 3: Predictors of the hazard of a recurrent AMI 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.48 [0.24, 0.97] 0.0397* 0.60 [0.29, 1.22] 0.1572 0.59 [0.30, 1.16] 0.1242 
71 - 75 years 0.54 [0.28, 1.03] 0.0597 0.49 [0.23, 1.03] 0.0601 0.48 [0.25, 0.93] 0.0302* 
76 - 80 years 0.50 [0.25, 0.99] 0.0470* 0.50 [0.24, 1.02] 0.0552 0.43 [0.21, 0.88] 0.0203* 
81 - 85 years 0.65 [0.34, 1.24] 0.1904 1.06 [0.56, 2.01] 0.8668 0.86 [0.46, 1.61] 0.6314 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.10 [0.69, 1.76] 0.6767 1.12 [0.68, 1.82] 0.6641 1.15 [0.72, 1.82] 0.5597 
Female Ref   Ref   Ref   
Ethnicity          
White 1.32 [0.62, 2.83] 0.4732 1.82 [0.71, 4.67] 0.211 0.86 [0.43, 1.71] 0.6649 
Other 1.04 [0.33, 3.29] 0.9518 1.90 [0.53, 6.82] 0.3237 0.53 [0.16, 1.75] 0.2953 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.84 [0.47, 1.50] 0.5572 0.89 [0.47, 1.69] 0.7172 0.64 [0.33, 1.22] 0.1713 
Midwest 0.67 [0.39, 1.17] 0.1619 0.77 [0.44, 1.36] 0.3675 0.67 [0.39, 1.16] 0.1485 
West 0.40 [0.18, 0.91] 0.0297* 0.63 [0.28, 1.38] 0.2429 0.75 [0.37, 1.49] 0.4040 
South Ref   Ref   Ref   
CCI 1.09 [1.01, 1.16] 0.0212* 1.13 [1.05, 1.22] 0.0009* 1.11 [1.04, 1.19] 0.0024* 
Length of Hospital Stay          
< 7 days 1.15 [0.69, 1.91] 0.5889 1.83 [1.01, 3.32] 0.0455* 1.38 [0.81, 2.32] 0.2335 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.43 [0.16, 1.16] 0.0971 0.71 [0.26, 1.97] 0.5152 0.66 [0.25, 1.80] 0.4202 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.49 [0.28, 0.84] 0.0099* 0.59 [0.34, 1.01] 0.0548 0.68 [0.41, 1.14] 0.1411 
Prior Angina 1.44 [0.80, 2.60] 0.2231 1.15 [0.58, 2.30] 0.6897 1.50 [0.84, 2.70] 0.1742 
Prior CAD 1.10 [0.67, 1.81] 0.7115 0.93 [0.55, 1.55] 0.7739 1.17 [0.71, 1.93] 0.5436 
Prior Therapy          
Prior Statin Therapy, 0.83 [0.51, 1.33] 0.4290 1.11 [0.67, 1.83] 0.6804 1.20 [0.75, 1.93] 0.4536 
Prior β-blocker Therapy 1.35 [0.84, 2.17] 0.2134 1.40 [0.84, 2.33] 0.2004 1.48 [0.91, 2.39] 0.1137 
Prior ACEI/ARB Therapy 0.92 [0.56, 1.51] 0.7476 1.18 [0.70, 1.98] 0.5329 0.80 [0.49, 1.31] 0.3753 
          
TIME-VARYING PREDICTORS          
Number of office/outpatient visits 1.00 [0.98, 1.02] 0.9813 0.99 [0.97, 1.02] 0.6353 1.00 [0.98, 1.03] 0.6992 
Hospitalization visit (any cause) 1.09 [0.47, 2.52] 0.8477 0.86 [0.31, 2.39] 0.7658 1.16 [0.54, 2.51] 0.7061 
Emergency room visit (any cause) 1.13 [0.56, 2.26] 0.7391 1.22 [0.57, 2.58] 0.6092 1.11 [0.55, 2.18] 0.7912 
Receipt of PCI and/or CABG 1.43 [0.30, 6.70] 0.6516 1.86 [0.37, 9.24] 0.4507 0.64 [0.08, 5.02] 0.6728 
Presence of claim related to risk factors 1.31 [0.72, 2.41] 0.3796 1.05 [0.58, 1.92] 0.8657 0.96 [0.55, 1.67] 0.8925 
Presence of claim related to low-survival rate 
conditions 
0.85 [0.47, 1.55] 0.4970 0.93 [0.48, 1.80] 0.8317 0.93 [0.51, 1.70] 0.8028 
Number of unique prescription claims 1.02 [0.96, 1.09] 0.4594 1.03 [0.96, 1.10] 0.4635 1.00 [0.94, 1.06] 0.9519 
Part D coverage gap 1.07 [0.67, 1.71] 0.7752 1.02 [0.62, 1.68] 0.9473 1.03 [0.65, 1.62] 0.9006 
Out-of-pocket Medicare costs† 1.00 [0.96, 1.03] 0.7845 1.00 [0.96, 1.04] 0.9457 1.00 [0.98, 1.02] 0.9010 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.61 [0.38, 0.97] 0.0366* 0.61 [0.35, 1.08] 0.0921 0.62 [0.36, 1.06] 0.0809 
Not on therapy ─ ─ ─ 0.87 [0.46, 1.64] 0.6658 0.75 [0.41, 1.39] 0.3642 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy          
Adherent 1.14 [0.62, 2.10] 0.6819 1.09 [0.65, 1.85] 0.7440 0.98 [0.54, 1.77] 0.9474 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
Not on therapy 1.12 [0.59, 2.11] 0.7350 ─ ─ ─ 0.88 [0.47, 1.65] 0.6932 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.26 [0.70, 2.27] 0.4410 1.17 [0.63, 2.17] 0.6266 1.57 [0.93, 2.68] 0.0942 
Not on therapy 0.85 [0.45, 1.61] 0.6130 0.87 [0.44, 1.71] 0.6862 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
†Costs were divided by 100 
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Mortality.  Table XI presents the results of a discrete-event time model estimating the effect of 
time-varying adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, and C, 
respectively, on the risk of death after accounting for time-varying covariates.  Time-varying 
adherence to statins was not significantly associated with the hazard of mortality (HR = 0.89; 
95% CI [0.63, 1.27]; p = 0.5243); neither was time-varying adherence to β-blockers (HR = 0.85; 
95% CI [0.59, 1.21]; p = 0.3638), nor ACEI/ARBs (HR = 0.98; 95% CI [0.70, 1.38]; p = 
0.9260). 
  Increasing age was associated with a higher hazard of mortality across all three cohorts.  
Patients aged 65-70 years (cohort A: HR = 0.35; 95% CI [0.21, 0.60]; p < .0001, cohort B: HR = 
0.23; 95% CI [0.13, 0.41]; p < .0001, cohort C: HR = 0.38; 95% CI [0.23, 0.63], p = 0.0002), 71-
75 years (cohort A: HR = 0.38; 95% CI [0.23, 0.62]; p = 0.0001, cohort B: HR = 0.26; 95% CI 
[0.16, 0.45]; p < .0001, cohort C: HR = 0.35; 95% CI [0.22, 0.55]; p < .0001), 76-80 years 
(cohort A: HR = 0.45; 95% CI [0.28, 0.73]; p = 0.0014, cohort B: HR = 0.29; 95% CI [0.18, 
0.47]; p < .0001, cohort C: HR = 0.45; 95% CI [0.29, 0.69]; p = 0.0003), and 81-85 (cohort B: 
HR = 0.60; 95% CI [0.39, 0.92]; p = 0.0196) years had a lower hazard of death in comparison to 
the elderly patients (> 85 years). 
 The hazard of death increased significantly with CCI (cohort A: HR = 1.08; 95% CI 
[1.03, 1.13]; p = 0.0017, cohort B: HR = 1.06; 95% CI [1.01, 1.13]; p = 0.0326, cohort C: HR = 
1.06; 95% CI [1.01, 1.11]; p = 0.0133).  Patients that had a CABG procedure performed during 
their initial AMI hospitalization event had a lower hazard of death, with reference to patients that 
did not have the procedure performed (cohort A: HR = 0.29; 95% CI [0.12, 0.68]; p = 0.0023, 
cohort B: HR = 0.31; 95% CI [0.14, 0.69]; p = 0.0041, cohort C: HR = 0.29; 95% CI [0.12, 
0.68]; p = 0.0046).  Similarly, a PCI procedure during the initial AMI hospitalization lowered the 
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Table XI Model 3: Predictors of the hazard of death 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.35 [0.21, 0.60] <.0001* 0.23 [0.13, 0.41] <.0001* 0.38 [0.23, 0.63] 0.0002* 
71 - 75 years 0.38 [0.23, 0.62] 0.0001* 0.26 [0.16, 0.45] <.0001* 0.35 [0.22, 0.55] <.0001* 
76 - 80 years 0.45 [0.28, 0.73] 0.0014* 0.29 [0.18, 0.47] <.0001* 0.45 [0.29, 0.69] 0.0003* 
81 - 85 years 0.68 [0.44, 1.06] 0.0858 0.60 [0.39, 0.92] 0.0196* 0.72 [0.48, 1.08] 0.1133 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.23 [0.88, 1.72] 0.2348 1.36 [0.96, 1.94] 0.0868 1.09 [0.79, 1.51] 0.6042 
Female Ref   Ref   Ref   
Ethnicity          
White 1.05 [0.64, 1.71] 0.8593 1.06 [0.61, 1.83] 0.8481 0.94 [0.59, 1.47] 0.7732 
Other 1.05 [0.51, 2.15] 0.9003 0.92 [0.40, 2.11] 0.8434 0.73 [0.35, 1.49] 0.3839 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.78 [0.50, 1.22] 0.2799 0.85 [0.54, 1.36] 0.5045 0.76 [0.50, 1.17] 0.2129 
Midwest 0.96 [0.65, 1.43] 0.8415 0.78 [0.53, 1.17] 0.2274 0.79 [0.54, 1.15] 0.2185 
West 0.76 [0.46, 1.28] 0.3094 0.67 [0.38, 1.20] 0.1779 0.87 [0.54, 1.40] 0.5610 
South Ref   Ref   Ref   
CCI 1.08 [1.03, 1.13] 0.0017* 1.06 [1.01, 1.13] 0.0326* 1.06 [1.01, 1.11] 0.0133* 
Length of Hospital Stay          
< 7 days 1.06 [0.74, 1.50] 0.7611 1.07 [0.74, 1.54] 0.7176 0.93 [0.68, 1.28] 0.6522 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.29 [0.13, 0.64] 0.0023* 0.31 [0.14, 0.69] 0.0041* 0.29 [0.12, 0.68] 0.0046* 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.32 [0.20, 0.50] <.0001* 0.32 [0.20, 0.52] <.0001* 0.37 [0.24, 0.56] <.0001* 
Prior Angina 1.05 [0.66, 1.68] 0.8340 0.71 [0.40, 1.25] 0.2347 1.04 [0.65, 1.65] 0.8796 
Prior CAD 0.92 [0.64, 1.33] 0.6505 1.09 [0.76, 1.56] 0.6583 1.06 [0.76, 1.49] 0.7244 
Prior Therapy          
Prior Statin Therapy, 0.92 [0.65, 1.31] 0.6571 1.03 [0.71, 1.48] 0.8814 0.88 [0.63, 1.22] 0.4313 
Prior β-blocker Therapy 0.78 [0.56, 1.10] 0.1548 1.23 [0.87, 1.76] 0.2431 0.74 [0.54, 1.01] 0.0556 
Prior ACEI/ARB Therapy 1.26 [0.88, 1.80] 0.2098 1.20 [0.83, 1.72] 0.3387 1.69 [1.17, 2.44] 0.0054* 
          
TIME-VARYING PREDICTORS          
Number of office/outpatient visits 1.01 [1.00, 1.02] 0.0133* 1.02 [1.00, 1.03] 0.0079* 1.01 [1.00, 1.02] 0.2038 
Hospitalization visit (any cause) 2.40 [1.54, 3.76] 0.0001* 1.76 [1.06, 2.90] 0.0282* 2.13 [1.40, 3.25] 0.0004* 
Emergency room visit (any cause) 2.06 [1.37, 3.10] 0.0005* 1.40 [0.91, 2.17] 0.1290 1.67 [1.12, 2.49] 0.0128* 
Receipt of PCI and/or CABG 0.18 [0.02, 1.30] 0.0888 0.52 [0.12, 2.24] 0.3835 0.17 [0.02, 1.26] 0.0824 
Presence of claim related to risk factors 0.78 [0.51, 1.19] 0.2429 0.77 [0.50, 1.17] 0.2218 0.80 [0.55, 1.16] 0.2311 
Presence of claim related to low-
survival rate conditions 
1.28 [0.88, 1.87] 0.2029 1.38 [0.91, 2.08] 0.1290 1.44 [1.00, 2.06] 0.0515 
Number of unique prescription claims 1.03 [0.99, 1.07] 0.1397 1.04 [1.00, 1.09] 0.0506 1.05 [1.01, 1.08] 0.0147* 
Part D coverage gap 0.99 [0.71, 1.38] 0.9285 1.19 [0.85, 1.68] 0.3178 0.93 [0.68, 1.26] 0.6432 
Out-of-pocket Medicare costs† 1.00 [0.99, 1.01] 0.8100 1.02 [1.00, 1.03] 0.0139* 1.00 [0.99, 1.02] 0.8517 
Recurrent AMI 0.54 [0.19, 1.53] 0.2472 0.47 [0.15, 1.55] 0.2163 0.54 [0.19, 1.50] 0.2348 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.89 [0.63, 1.27] 0.5243 1.08 [0.68, 1.71] 0.7408 1.04 [0.68, 1.61] 0.8453 
Not on therapy ─ ─ ─ 1.70 [1.06, 2.73] 0.0274* 1.62 [1.04, 2.53] 0.0320* 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy   
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
Adherent 0.96 [0.61, 1.49] 0.8493 0.85 [0.59, 1.21] 0.3638 0.86 [0.56, 1.31] 0.4788 
Not on therapy 1.00 [0.64, 1.56] 0.9870 ─ ─ ─ 0.92 [0.61, 1.39] 0.6883 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.04 [0.68, 1.61] 0.8437 1.07 [0.69, 1.67] 0.7605 0.98 [0.70, 1.38] 0.9260 
Not on therapy 1.03 [0.65, 1.63] 0.8892 0.99 [0.62, 1.57] 0.9527 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
†Costs were divided by 100.
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hazard of death for patients, when compared to not having the procedure (cohort A: HR = 0.32; 
95% CI [0.20, 0.50]; p < .0001, cohort B: HR = 0.32; 95% CI [0.20, 0.52]; p < .0001, cohort C: 
HR = 0.37; 95% CI [0.24, 0.56]; p < .0001).  Cohort C patients that were on ACEI/ARB therapy 
prior to the initial AMI episode had a higher hazard of death, when compared to those that were 
not on prior ACEI/ARB therapy (HR = 1.69; 95% CI [1.17, 2.44]; p = 0.0054).   
 The hazard of death increased, corresponding to an increase in the number of 
office/outpatient visits in each quarter (cohort A: HR = 1.01; 95% CI [1.00, 1.02]; p = 0.0133, 
cohort B: HR = 1.02; 95% CI [1.00, 1.03]; p = 0.0079).  Patients that had a hospitalization 
episode in an observed quarter had a significantly higher hazard of death (cohort A: HR = 2.40; 
95% CI [1.54, 3.76]; p = 0.0001, cohort B: HR = 1.76; 95% CI [1.06, 2.90]; p = 0.0282, cohort 
C: HR = 2.13; 95% CI [1.40, 3.25]; p = 0.0004), when compared to patients that did not 
experience a hospitalization event in that quarter.  Similarly, having an emergency room event in 
a quarter increased the hazard of death (cohort A: HR = 2.06; 95% CI [1.37, 3.10]; p = 0.0005, 
cohort C: HR = 1.67; 95% CI [1.12, 2.49]; p = 0.0128), with reference to not having such an 
episode.  Among cohort C patients, an increase in the number of unique prescriptions per quarter 
increased the risk of death (HR = 1.05; 95% CI [1.01, 1.08]; p = 0.0147).  Higher out-of-pocket 
Medicare costs increased the hazard of death among cohort B patients (HR = 1.02; 95% CI [1.00, 
1.03]; p = 0.0139). 
 Among cohorts B and C, a higher hazard of death was observed among patients that were 
not on concomitant statin therapy, when compared to those that were not adherent to their 
concomitant statin therapy (cohort B: HR = 1.70; 95% CI [1.06, 2.73]; p = 0.0274, cohort C: HR 
= 1.62; 95% CI [1.04, 2.53]; p = 0.0320). 
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 The results of continuous time models (model 3b) estimating the effect of time-varying 
adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, and C, respectively, on 
the risk of subsequent outcomes, accounting for time-varying covariates, are presented in 
Appendix C – Additional Results, Tables XXV and XXVI. 
Model 4: Marginal structural model 
Across the observed person-quarters for cohort A, the average stabilized weight was 5.08 
(±89.38) and median was 0.97 (Table XII).  For cohort B the average stabilized weight was 
17.94 (±379.45) with median weight 0.96.  Finally, for cohort C the average stabilized weight 
was 81.78 (±3,097.91) with a median of 0.96 and range of 241,123.83.   
Table XII Stabilized weights 
  Stabilized Weights 
Person Quarters Mean Std. Dev. Median Range 
Cohort A (Statin Therapy) 8,497 5.08 89.38 0.97 5,409.55 
Cohort B (β-blocker Therapy)  7,920 17.94 379.45 0.96 20,074.42 
Cohort C (ACEI/ARB Therapy) 7,832 81.78 3,097.91 0.96 241,123.83 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker 
 
Figure IV displays the temporal distribution of the log of stabilized weights in cohort A.  
Similarly, Figures V and VI display the temporal distribution of the log of stabilized weights in 
cohorts B and C, respectively. 
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Figure IV Log of stabilized weights across quarters in cohort A (statin therapy)
 
Figure V Log of stabilized weights across quarters in cohort B (β-blocker therapy) 
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Figure VI Log of stabilized weights across quarters in cohort C (ACEI/ARB therapy) 
 
The adjusted HRs from MSMs estimating the effect of time-varying adherence to statin, 
β-blocker, and ACEI/ARB therapy in cohorts A, B, and C, respectively, on the risk of 
subsequent outcomes are presented in Table XIII. 
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Table XIII Model 4: Adjusted hazard ratios (HRs) from marginal structural models (MSMs) 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
RECURRENT AMI          
Statin Adherence 0.64 [0.36, 1.15] 0.1370       
β-blocker Adherence    0.75 [0.43, 1.33] 0.3270    
ACEI/ARB Adherence       1.19 [0.55, 2.61] 0.6566 
             
MORTALITY          
Statin Adherence 0.91 [0.58, 1.43] 0.6772       
β-blocker Adherence    0.71 [0.40, 1.25] 0.2322    
ACEI/ARB Adherence             1.64 [0.78, 3.47] 0.1193 
*p<0.05 
HR, Hazards Ratio; AMI, acute myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker 
 
Refer to Appendix C – Additional Results for the distribution of normalized weights across all quarters for all three study 
cohorts (Table XXVII, Figures X, XI, and XII) and adjusted HRs from MSMs using normalized weights (Table XXVIII), to estimate 
the effect of time-varying adherence to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, and C, respectively, on the risk of 
subsequent outcomes.
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Aim 4: Comparison of Predictive Values of Adherence Measured as a Time-varying 
and Time-invariant Variable 
The adjusted HRs from various models discussed above, estimating the effect of adherence 
(time-varying and time-invariant) to statin, β-blocker, and ACEI/ARB therapy in cohorts A, B, 
and C, respectively, on the risk of subsequent outcomes are presented in Table XIV.  Statin 
adherence, measured as varying over 90 day periods, was associated with a lower risk of a 
recurrent AMI in discrete-event time models 2 (baseline covariates + time-varying adherence) 
and 3 (baseline covariates +  time-varying adherence + time-varying covariates) in cohort A.  
When accounting only for baseline covariates (model 2), the hazard for a recurrent AMI among 
statin adherent patients in cohort A was 63% of the hazard among non-adherent patients (HR = 
0.63; 95% CI [0.40, 0.99]; p = 0.0471).  When accounting for baseline covariates and time-
varying covariates (model 3), the hazard for a recurrent AMI among statin adherent patients in 
cohort A was 61% of the hazard among non-adherent patients (HR = 0.61, 95% CI [0.38, 0.97]; 
p = 0.0366). 
Table XV presents model fits statistics for the various models fit to the data.  Discrete-
event time models (2 and 3) have the best model fit statistics across all three cohorts while 
estimating the effect of adherence of subsequent outcomes.  On the other hand, MSMs displayed 
the worst fit statistics.
82 
 
Table XIV Adjusted HRs estimating the effect of adherence on subsequent outcomes across various models 
 Cohort A (Statin Therapy)  Cohort B (β-blocker Therapy)  Cohort C (ACEI/ARB Therapy)  
  N = 1,091 N = 1,021 N = 1,025 
 HR 95% CI p HR 95% CI p HR 95% CI p 
RECURRENT AMI                 
Model 1  0.73 [0.47, 1.15] 0.1707 0.95 [0.59, 1.54] 0.8435 0.98 [0.61, 1.58] 0.9381 
Model 2  0.63 [0.40, 0.99] 0.0471* 1.12 [0.67, 1.89] 0.6622 1.57 [0.93, 2.67] 0.0931 
Model 3  0.61 [0.38, 0.97] 0.0366* 1.09 [0.65, 1.85] 0.7440 1.57 [0.93, 2.68] 0.0942 
Model 4 0.64 [0.36, 1.15] 0.1370 0.75 [0.43, 1.33] 0.3270 1.19 [0.55, 2.61] 0.6566 
          
MORTALITY          
Model 1 0.73 [0.53, 1.00] 0.0531 1.21 [0.86, 1.71] 0.2704 1.04 [0.75, 1.44] 0.8215 
Model 2 0.86 [0.61, 1.21] 0.3913 0.97 [0.68, 1.38] 0.8469 1.04 [0.74, 1.46] 0.8189 
Model 3 0.89 [0.63, 1.27] 0.5243 0.85 [0.59, 1.21] 0.3638 0.98 [0.70, 1.38] 0.9260 
Model 4 0.91 [0.58, 1.43] 0.6772 0.71 [0.40, 1.25] 0.2322 1.64 [0.78, 3.47] 0.1193 
*p<0.05 
HR, Hazards Ratio; AMI, acute myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker 
Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-varying adherence; Model 3: Baseline covariates + time-
varying predictors + time-varying adherence; Model 4: Marginal structural model
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Table XV Model fit statistics 
  Cohort A (Statin Therapy)  Cohort B (β-blocker Therapy)  Cohort C (ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  -2 Log L  AIC BIC  -2 Log L AIC BIC  -2 Log L AIC BIC 
RECURRENT AMI                  
Model 1  1123.78 1167.78 1221.78 995.82 1039.82 1091.67 1120.9 1164.90 1219.15 
Model 2  836.44 884.44 943.34 763.35 811.35 867.91 838.10 886.097 945.28 
Model 3  833.56 899.56 980.56 761.75 827.75 905.52 837.16 903.16 984.54 
Model 4 2069.40 2109.40 2158.48 8335.92 8375.92 8423.05 3690.06 3730.06 3779.374 
          
MORTALITY          
Model 1 2072.58 2116.58 2184.77 1955.52 1999.52 2066.89 2351.63 2395.63 2466.95 
Model 2 1392.38 1440.38 1514.77 1286.02 1334.02 1407.52 1516.26 1564.26 1624.06 
Model 3 1321.18 1389.18 1494.58 1224.95 1292.95 1397.08 1461.62 1529.62 1639.84 
Model 4 3342.77 3382.77 3444.76 7891.38 7931.38 7992.63 6407.54 6447.54 6512.38 
-2 Log L, -2 log likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; AMI, acute myocardial 
infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker 
Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-varying adherence; Model 3: Baseline covariates + time-
varying predictors + time-varying adherence; Model 4: Marginal structural model
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Sensitivity Analysis 
Adjusted HRs estimating the effect of adherence on subsequent outcomes in cohort A at different 
cut-offs for defining patients as adherent (40% and 90%), across the various models are reported 
in Table XVI.  Similarly, Tables XVII and XVIII present the adjusted HRs in cohorts B and C, 
respectively. 
Table XVI Sensitivity analysis - cohort A (statin therapy) 
  Adherence cut-offs  
 40% 90% 
  HR 95% CI p HR 95% CI p 
RECURRENT AMI           
Model 1  0.75 [0.41, 1.40] 0.3693 0.81 [0.53, 1.26] 0.3534 
Model 2  0.65 [0.42, 1.02] 0.0632 0.65 [0.42, 1.02] 0.0632 
Model 3  0.64 [0.40, 1.01] 0.0524 0.64 [0.40, 1.01] 0.0524 
Model 4 0.77 [0.33, 1.82] 0.5484 0.72 [0.39, 1.33] 0.2965 
       
MORTALITY       
Model 1 0.86 [0.55, 1.37] 0.5291 0.73 [0.53, 1.00] 0.0487* 
Model 2 0.70 [0.47, 1.03] 0.0671 0.88 [0.63, 1.23] 0.4500 
Model 3 0.65 [0.44, 0.97] 0.0341* 0.88 [0.63, 1.23] 0.4654 
Model 4 0.72 [0.40, 1.31] 0.2879 0.59 [0.33, 1.05] 0.0748 
*p<0.05 
HR, Hazards Ratio; AMI, acute myocardial infarction;  
Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-varying adherence; 
Model 3: Baseline covariates + time-varying predictors + time-varying adherence; Model 4: 
Marginal structural model 
Table XVII Sensitivity analysis - cohort B (β-blocker therapy) 
  Adherence cut-offs   
 40% 90% 
  HR 95% CI p HR 95% CI p 
RECURRENT AMI           
Model 1  1.65 [0.70, 3.90] 0.2539 1.00 [0.63, 1.57] 0.9837 
Model 2  1.09 [0.66, 1.80] 0.7364 1.09 [0.66, 1.80] 0.7364 
Model 3  1.07 [0.64, 1.77] 0.8020 1.07 [0.64, 1.77] 0.8020 
Model 4 1.00 [0.54, 1.87] 0.9955 0.97 [0.54, 1.73] 0.9157 
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  Adherence cut-offs   
 40% 90% 
  HR 95% CI p HR 95% CI p 
MORTALITY       
Model 1 1.85 [1.05, 3.26] 0.0342* 1.04 [0.75, 1.43] 0.8191 
Model 2 1.04 [0.67, 1.63] 0.8486 1.11 [0.78, 1.58] 0.5555 
Model 3 0.85 [0.55, 1.34] 0.4927 0.99 [0.70, 1.41] 0.9475 
Model 4 0.38 [0.19, 0.77] 0.0075* 1.05 [0.60, 1.84] 0.8642 
*p<0.05 
HR, Hazards Ratio; AMI, acute myocardial infarction;  
Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-varying adherence; 
Model 3: Baseline covariates + time-varying predictors + time-varying adherence; Model 4: 
Marginal structural model 
Table XVIII Sensitivity analysis - cohort C (ACEI/ARB therapy) 
  Adherence cut-offs  
 40% 90% 
  HR 95% CI p HR 95% CI p 
RECURRENT AMI           
Model 1  1.06 [0.57, 2.00] 0.8514 1.22 [0.77, 1.92] 0.4010 
Model 2  1.60 [0.97, 2.66] 0.0678 1.60 [0.97, 2.66] 0.0678 
Model 3  1.61 [0.97, 2.68] 0.0656 1.61 [0.97, 2.68] 0.0656 
Model 4 1.50 [0.40, 5.58] 0.5439 1.48 [0.60, 3.67] 0.3941 
       
MORTALITY       
Model 1 1.27 [0.77, 2.08] 0.3537 1.19 [0.88, 1.62] 0.2612 
Model 2 1.38 [0.89, 2.13] 0.1481 1.02 [0.73, 1.41] 0.9222 
Model 3 1.30 [0.84, 2.00] 0.2425 0.99 [0.72, 1.37] 0.9526 
Model 4 2.02 [0.70, 5.88] 0.1966 0.97 [0.57, 1.67] 0.9155 
*p<0.05 
HR, Hazards Ratio; AMI, acute myocardial infarction; ACEI, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker 
Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-varying adherence; 
Model 3: Baseline covariates + time-varying predictors + time-varying adherence; Model 4: 
Marginal structural model 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
This study explores the relationship between long-term adherence to secondary prevention 
therapies post-AMI and subsequent outcomes, specifically, recurrent AMI and mortality, using 
the 5% Medicare random national sample data 2006 - 2008.  Using a retrospective cohort study 
design, estimates of the causal effect of time-invariant and time-varying measures of adherence 
to statin, β-blocker and ACEI/ARB therapy post-AMI on the risk of a recurrent AMI and 
mortality are reported, using various statistical models.  Estimates from MSMs accounting for 
time-dependent confounding have also been reported.  
 Among cohort A patients, 60.71% were found to be adherent to their statin therapy over 
the first year post-AMI.  Similarly, 61.39% and 56.05% were found to be adherent to β-blocker 
(cohort B) and ACEI/ARB (cohort C) therapy, respectively.  Studies have documented a wide 
range of adherence and compliance rates to these drug classes post-AMI (Benner et al. 2002; 
Kramer et al., 2006; Schneeweiss, Patirck, Maclure, Dormuth, & Glynn, 2007; Simpson et al., 
2003).  However, different definitions of adherence/compliance, different time periods of 
measurement, and widely differing populations make it extremely essential that these statistics 
be compared with caution.  Rasmussen et al. (2007) measured adherence to statins, β-blockers 
and calcium channel blockers over a period of one year post-AMI among the elderly and 
categorized patients with proportion of days covered (PDC) ≥80% as adherent; 80.5% and 73.5% 
were documented to be adherent to statin and β-blocker therapy, respectively.  The study was 
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conducted on a population based in Ontario, which has different health insurance policies for 
prescription medications for the elderly (Jackevius et al., 2002), among other differences, which 
could have led to the higher reported adherence rates.  This does, however, pose an important 
question on our current policies governing prescription medication insurance for the elderly such 
as the ‘donut hole’ and its impact on adherence and subsequent outcomes.  The adherence 
estimates are comparable to the summary estimate of 57% for adherence to primary and 
secondary prevention therapies provided by a recent meta-analysis of observational studies 
(Naderi et al., 2012).  Patients who had at least 75% of days covered for a specific drug over a 
specified time period were classified as adherent in the meta-analysis. 
 Age emerged as a statistically significant predictor of adherence to β-blocker therapy, 
however, the same was not observed for adherence to statin or ACEI/ARB therapy.  Among 
cohort B patients, >85 year olds were less likely to adhere to β-blocker therapy.  Possible reasons 
could be increasingly complex drug regimens which also lead to lack of sufficient funds with the 
elderly approaching the ‘donut hole’ in their Part D prescription coverage and widowhood 
(Osterberg, & Blaschke, 2005; Schneeweiss et al., 2007; Zhang, Donohue, Lave, O’Donnell, & 
Newhouse, 2009).  The study reported females to more likely be adherent to β-blocker therapy 
than males, however, gender was not a significant predictor of adherence to statin or ACEI/ARB 
therapy.  Although this relationship between gender and β-blocker therapy adherence has been 
documented elsewhere (Gislason et al., 2006); this finding is not consistent across studies.  
White patients were more likely to be adherent to statin therapy in comparison to Black patients.  
This relationship has been supported previously in the literature (Monane et al., 1996; Sharkness, 
& Snow, 1992), with possible reasons cited being differences in health-related beliefs and 
socioeconomic status.  Differences in socioeconomic status could also be the underlying 
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explanation for patients in the Northeast being more likely to adhere to β-blocker therapy than 
patients residing in the South of US.  However, none of the demographic factors emerged as 
statistically significant predictors of adherence across all three cohorts.  The reported 
associations between these factors and medication adherence in the literature have been 
inconsistent (Avorn et al., 1998; Balkrishnan, 1998; Kulkarni, Alexander, Lytie, Heiss, & 
Peterson, 2006; Monane et al., 1997).  Prior therapy with statins was associated with 
significantly higher adherence post-AMI to statins.  This association was also observed for β-
blocker and ACEI/ARB therapy.  Rasmussen et al.’s (2007) population-based, observational 
study of elderly AMI survivors in Ontario reported the same finding, suggesting medication use 
preceding index AMI hospitalization improves adherence to these medication regimens post-
AMI. 
 Patients that are comparatively older during their initial AMI and those with a severe 
comorbid profile were more likely to suffer a recurrent episode.  Increasing age and CCI were 
also associated with a higher hazard of death.  Additionally, patients from the West have a lower 
hazard of a recurrent AMI when compared to patients from the South.  This can be explained via 
the higher obesity rates and higher prevalence of risk factors of CVD among the southern 
population (Roger et al., 2012).  However, recent data from the Centers for Disease Control and 
Prevention National Environmental Public Health Tracking Network has reported that age-
adjusted acute myocardial infarction hospitalization rates are the highest in the Northeastern 
states (Talbott et al., 2013).   The risk of a recurrent AMI and mortality was found to be lower 
among patients that had a PCI performed during their initial hospitalization, which is consistent 
with prior reports (Chen et al., 2010).  A similar association was found between the performance 
of CABG and the hazard of mortality.  Interestingly, patients with a hospitalization stay of <7 
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days for their initial AMI episode were found to have a higher risk of recurrent AMI.  
Traditionally, length of hospital stay (LOS) has been associated with severity of disease, 
whereby a longer LOS would imply higher severity.  Such patients would therefore be more 
likely to be readmitted.  However, with hospitals aggressively trying to decrease LOS, excessive 
LOS reduction, especially for certain conditions may be harmful because discharge before 
medical stability may result in increased hospital readmission rates.  Patients on ACEI/ARB 
therapy prior to the initial AMI were found to have a higher hazard of mortality across all 
models.  Patients that are on ACEI/ARB therapy prior to initial AMI probably have a different 
comorbidity/severity profile that may explain the higher hazard of mortality among such 
patients.   
A significant contribution of this study is the finding that patients that are not on statin 
therapy among the ACEI/ARB and β-blocker users had an approximately 60% higher hazard of 
death when compared to patients that were not adherent to statin therapy.  This result was 
reported across models with and without time-varying predictors.  Since the end-point here was 
all cause mortality and not just cardiovascular mortality this finding supports the various studies 
that have been published recently on the various beneficial pleiotropic effects of statins (Endres, 
2006; Ganotakis, Mikhailidis, & Vardas, 2006; Lokhandwala, West-Strum, Banahan, Bentley & 
Yang, 2012; Paraskevas, Tzovaras, Briana, & Mikhailidis, 2007).   Statins have been shown to 
improve endothelial dysfunction, increase nitric oxide bioavailability, have antioxidant 
properties, inhibit inflammatory responses, and stabilize atherosclerotic plaques (Davignon, 
2004).  Although prior studies have demonstrated the beneficial effects of statin beyond its 
cardiovascular effects, this study adds significantly to that by suggesting that not being on statins 
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is much worse than not being adherent to them.  A similar effect was not observed for 
ACEI/ARBs or β-blockers. 
The presence of a hospitalization visit in a quarter was associated with an increased 
hazard of death across all three study cohorts.  Further, the number of office/outpatient visits, 
presence of an ER visit, number of unique prescription claims and out-of pocket Medicare costs 
were found to increase the hazard of death.  However, these results were observed in one or two 
of the study cohorts, but not across cohorts A, B, and C.  All of the above mentioned variables 
can be used as indicators of disease severity and hence their association with an increased hazard 
of death is not surprising. 
A statistically significant protective effect of long-term adherence on subsequent 
outcomes was only observed among statin users where adherence was measured as a time-
varying covariate.  The hazard of a recurrent AMI among patients adherent to statin was 63% 
(HR = 0.63; 95% CI [0.40, 0.99]; p = 0.0471) that of non-adherent patient when only baseline 
covariates were included in the model.  On including time-varying covariates, the hazard of a 
recurrent AMI for adherent patients dropped to 61% of that for non-adherent patients (HR = 
0.61, 95% CI [0.38, 0.97]; p = 0.0366).  A statistically significant protective effect of long-term 
adherence to β-blockers on subsequent outcomes was not observed.  Similarly, long-term 
adherence to ACEI/ARBs did not have a statistically significant protective effect against 
recurrent AMI or mortality in this study.  Additionally, most of the hazard ratios for the effect of 
long-term adherence to ACEI/ARBs on subsequent outcomes across all models were found to be 
above 1, suggesting an opposite effect, although not statistically significant.   
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The results from the MSMs for the effect of long-term adherence to secondary prevention 
therapies post-AMI on subsequent outcomes were not statistically significant.  The hazard ratios 
from the MSMs were found to be less than 1, for the effect of adherence to statins and β-blockers 
on both subsequent outcomes, i.e., recurrent AMI and all-cause mortality.  However, this was not 
true for the effect of adherence to ACEI/ARBs on subsequent outcomes.   
When comparing the hazard ratios across all models for the effect of long-term adherence 
to statin therapy on recurrent AMI (Figure VII) and all-cause mortality (Figure VIII), it is 
interesting to note that the protective effect of adherence to statin on recurrent AMI seems to 
become stronger across the models 1 through 4.  The reverse trend is observed for the effect of 
adherence to statins on all-cause mortality. However, these results are not statistically significant, 
and therefore should be interpreted with caution.  
 
Figure VII Adjusted hazard ratios estimating the effect of statin adherence (cohort A) on 
recurrent AMI. Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-
varying adherence; Model 3: Baseline covariates + time-varying predictors + time-varying 
adherence; Model 4: Marginal structural model. 
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Figure VIII Adjusted hazard ratios estimating the effect of statin adherence (cohort A) on 
mortality. Model 1: Time-invariant adherence; Model 2: Baseline covariates + time-
varying adherence; Model 3: Baseline covariates + time-varying predictors + time-varying 
adherence; Model 4: Marginal structural model. 
Models 2 and 3, i.e., the models with time-varying adherence with and without time-
varying predictors were found to have the best goodness-of-fit statistics.  A possible reason for 
the observed results from the MSMs and poor goodness-of-fit could be the comparatively higher 
variability of the stabilized weights.  The recent study by Yu et al. (2010) shows the application 
of MSMs over conventional models, where the protective effect of adherence to hypoglycemics 
was only observed with MSMs.  However, combining all patient-quarters, the mean of the 
stabilized weights in their study was 1.37(±19.57) and median 0.81.  In comparison, the mean of 
the stabilized weights across all patient-quarters in this study for cohort A was 5.08 (±89.38) and 
median 0.97.  The mean and standard deviation of stabilized weights for cohorts B and C were 
much higher.  Very few patients were observed through all 11 quarters, which could lead to 
highly variable weights. 
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In order to reduce the variability of the weights in each risk set over time, normalized 
weights were computed and used in estimation of the MSMs (Xiao et al., 2010).  Combining all 
patient-quarters, the standard deviation of the normalized weights was 4.36 for cohort A and the 
observed median was 0.67.  For cohorts B and C the standard deviation of the normalized 
weights was 5.09 and 6.46, respectively, with a median of 0.44 and 0.43, respectively.  Using 
normalized weights in the estimation of MSMs, long-term adherence to statin was associated 
with a statistically significant reduction in the hazard of a recurrent AMI (HR =0.60; 95% CI 
[0.37, 0.95]; p = 0.0312). 
The consistency of the IPTW estimator relies on the positivity assumption (Neugebauer, 
& van der Laan, 2005; Wang, Petersen, Bangsberg, & van der Laan, 2006; Cole, & Hernan, 
2008).  Essentially, each subject should have a positive probability of being exposed to each 
level of treatment, i.e., being adherent or non-adherent in our study population.  This assumption 
can be practically violated when the subjects in a subgroup with a particular combination of 
covariates have an extremely low probability of being adherent, that they were in fact adherent 
will lead to them being assigned large weights (Xiao, Moodie, & Abrahamowicz, 2013).  These 
weights get magnified by the multiplication of the probabilities over the follow-up time, leading 
to instability of the estimator.  Normalized weights can be used to reduce the variability of the 
weights.  However, when the covariate-treatment association is very strong this might still lead 
to issues in estimation.  In such cases other approaches have been proposed in the literature to 
deal with estimation issues arising from highly variable weights.  These include (i) truncation of 
weights (Kish, 1992; Wang et al., 2006; Bembom, & van der Laan, 2008a; Cole, & Hernan, 
2008; Moore, Neugebauer, & van der Laan, 2009), (ii) G-computation (van der Wal, Prins, 
Lumbreras, & Geskus, 2009), (iii) exclusion of certain covariates that lead to high covariate-
94 
 
treatment association but are weakly associated with the outcome (Bembom, & van der Laan, 
2008b), (iv) ‘trimming’, i.e., exclusion of observations that lead to issues (LaLonde, 1986; 
Heckman, Ichimura, & Todd, 1998; Dehejia, & Wahba; 1999; Crump, Hotz, Imbens, & Mitnik, 
2006), and (v) history-restricted MSMs where a limited portion of the treatment history is used 
for MSM estimation (Neugebauer, et al., 2007).  The utilization of these approaches with the 
present data should be evaluated for future research. 
In addition to the variability of the weights, this research has several limitations that need 
to be acknowledged.  The study uses observational data for analysis.  This could lead to errors 
due to misclassification resulting from coding errors while claims processing.  Adherence was 
computed using prescription claim data.  The presence of a claim for a drug does not necessarily 
imply that the drug was administered.  However, previous studies have shown that observational 
data provide a good tool for conducting adherence studies.  Further, adherence in the study 
period was dichotomized at the 80% mark into adherent and non-adherent categories to make 
interpretation easier and intuitive.  However, sensitivity analyses were conducted using different 
cutoff points, so as to corroborate the conclusions.  An interesting finding of the sensitivity 
analyses was that patients on β-blockers when classified as adherent at a cut-off of 40% were 
found to have a 38% (HR = 0.38; 95% CI [0.19, 0.77]; p = 0.0075) hazard of mortality when 
compared to non-adherent patients via MSM estimators. The results of the model estimating the 
effect of time-invariant β-blocker adherence on the hazard of mortality suggested a detrimental 
effect of being adherent (HR = 1.85; 95% CI [1.05, 3.26]; p = 0.0342).  Figure IX shows the 
results of models 2 and 3 too, in addition to the above results.  These results mirror the effect 
documented by Yu et al. (2010).  They estimated the effects of medication adherence to 
hypoglycemics on the risk of micro vascular complications in type 2 diabetes patients.  The Cox 
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models with time-invariant and time-varying adherence measures, and after accounting for time-
varying covariates, presented a detrimental effect of higher adherence.  The estimates from 
MSM, however, suggested that higher medication adherence may results in a reduced risk of 
micro vascular complications among patients with type 2 diabetes.   The covariate-treatment 
association is most likely weaker when adherence to β-blockers is cut-off at 40%, thus, 
explaining the results of the sensitivity analysis.  This also implies that reduced adherence to β-
blockers does have an impact on the hazard of mortality; patients are better off having less than 
perfect adherence than being completely off the drug. 
 
Figure IX Adjusted hazard ratios estimating the effect of β-blocker adherence (cohort B) 
on mortality when adherence is cut-off at 40%. Model 1: Time-invariant adherence; Model 
2: Baseline covariates + time-varying adherence; Model 3: Baseline covariates + time-
varying predictors + time-varying adherence; Model 4: Marginal structural model. 
  Another limitation is the population of the study.  The study was conducted among 
elderly AMI patients.  Given their higher baseline cardiovascular risk and lower tolerance to 
multiple medication regimes, they are the most vulnerable population.  These variations in 
baseline cardiovascular risk and compliance profiles may alter the magnitude of association 
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between adherence and subsequent outcomes; hence the results should be extended to other age 
groups with caution.  Using cardiovascular mortality as the end-point, rather than all-cause 
mortality would have led to richer results.  Unfortunately, data on the cause of death was not 
available. 
 One of the assumptions necessary for causal inference using MSMs is the presence of no 
unmeasured confounders.  Although, the relevant literature has been thoroughly scanned to 
include potential predictors, there are certain risk factors such as smoking, low-density 
lipoprotein levels, body weight, and blood pressure that are not measurable using observational 
data.  In addition over-the-counter medication use (for e.g., aspirin) cannot be tracked.  
Information on adverse reactions, allergies, or intolerance, all of which are associated with 
medication discontinuation was not available.  Observational data does, however, offer 
considerable advantages in terms of feasibility and more observation points for cheaper.  Perhaps 
future studies can investigate feasible ways of acquiring information on the additional covariates 
for use with those considered in the study. 
This study only estimates the effect of long-term adherence to secondary prevention 
therapies on recurrent AMI and mortality.  Future studies can investigate this relationship using 
different outcomes, such as costs.  This research question can be explored using different data 
such as MarketScan Commercial and Medicare, in order to avoid problems arising from few 
patients followed for the entire length of time.  The benefits of using MSMs over other statistical 
techniques, or the benefits of using time-varying measures of adherence versus time-invariant 
measures can be further investigated among a different population with a different condition.  
The time-varying nature of adherence can also be investigated by studying the rate of change of 
adherence over time.  The effect of various factors on the rate of change can be estimated using 
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multilevel models.  Exploring adherence as a time-varying measure offers a wide range of 
avenues for future research. 
This study documents adherence rates to secondary prevention therapies post-AMI in the 
Medicare population, as well as healthcare utilization rates in terms of hospitalizations, ER, and 
office visits over three-month windows.  This study also contributes significantly from a 
methodological perspective.  Different statistical models have been compared while measuring 
adherence as time-invariant and time-varying.  Time-dependent confounding has also been 
accounted for.  There is a lack of studies estimating the effect of long-term adherence to 
secondary prevention therapies on subsequent outcomes while accounting for time-dependent 
confounding.  It is imperative to understand this relationship with the clinical and economic 
burden of cardiovascular diseases being relatively high among Americans.  With observational 
studies being the most pragmatic way of studying this relationship, it is essential to better our 
methodology to approach the research question under consideration.  This study is a step in that 
direction.  There are not many studies where the results do not suggest MSMs as the superior 
approach to handle time-dependent confounding issues.  However, it is important to note here 
that publication bias could be an explanation, as studies that do not find differences between 
standard methods and MSMs probably do not get published.  Taking note of this, further studies 
are required to understand if MSMs should be the preferred methodology when exploring the 
relationship between long-term medication adherence and health outcomes. 
In conclusion, the purpose of this study was to estimate the effect of long-term adherence 
to secondary prevention therapies post-AMI on subsequent cardiovascular outcomes. Time-
invariant and time-varying measures of adherence were computed.  A longitudinal cohort 
observational study design was employed using the retrospective Medicare 5% random national 
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sample claims data from January 1
st
, 2006 to December 31
st, 
2008.  Estimates of the effect of 
adherence from Cox regression models and MSMs were compared, along with model-fit-
statistics.  Adherence to statin therapy, measured as varying over time was associated with a 
reduced risk of a recurrent AMI in the discrete-event time models.  However, the results for the 
effect of adherence to β-blockers and ACEI/ARBs on subsequent cardiovascular events were not 
statistically significant.  Further studies are required to better understand if MSMs should be the 
preferred methodology when exploring the relationship between long-term medication adherence 
and health outcomes. 
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Table XIX ICD-9-CM diagnosis and procedure codes 
Condition ICD-9-CM Diagnosis and Procedure Codes 
Acute Myocardial 
Infarction 
410.x0, 410.x1 
Angina 413.xx 
Asthma 439.xx 
Cancer 140.xx – 172.xx, 174-198.xx, 199.1, 200.xx-208.xx 
Cerebrovascular Disease 430.xx – 438.xx 
Chronic Kidney Disease 403.xx, 404.xx, 582.xx, 583.xx, 585.xx, 586.xx, 588.xx 
Chronic Obstructive 
Pulmonary Disease 
491.20, 491.21, 492.0x, 492.8x, 496.xx, 518.1x, 518.2x, 506.4x  
Congestive Heart Failure 428.xx 
Coronary Artery Bypass 
Graft Surgery 
36.10-36.19 
Coronary Artery Disease 414.xx 
Diabetes 250.xx 
Dyslipidemia 272.0x – 272.4x 
Hypertension 401.xx 
Partial AV Block 426.0x, 426.12, 426.13, 426.2x – 426.4x, 426.51 – 426.54, 426.7 
Percutaneous Coronary 
Intervention 
36.01-36.09 
Peripheral Vascular 
Disease 
443.9x, 785.4x, v43.4x, 411.xx 
Sinus Bradycardia 427.81 
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β-Blocker Medications  
 acebutolol HCL  
 atenolol  
 betaxolol HCL  
 bisoprolol fumarate  
 carteolol HCL  
 carvedilol  
 labetalol HCL  
 metoprolol succinate  
 metoprolol tartrate  
 nadolol  
 nebivolol HCL  
 penbutolol sulfate  
 pindolol  
 propranolol HCL  
 timolol maleate 
β-Blocker Combination Products  
 atenolol & chlorthalidone  
 bisoprolol & HCTZ  
 nadolol & bendroflumethiazide  
 metoprolol & HCTZ  
 propranolol & HCTZ  
 timolol & HCTZ 
Statin Medications  
 lovastatin  
 rosuvastatin  
 fluvastatin  
 atorvastatin  
 pravastatin  
 simvastatin 
Statin Combination Products 
 niacin & lovastatin  
 atorvastatin & amlodipine  
 niacin & simvastatin  
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 pravastatin & aspirin  
 ezetimibe & simvastatin 
ARB Medications 
 candesartan  
 eprosartan  
 irbesartan  
 losartan  
 olmesartan  
 telmisartan  
 valsartan 
ACEI Medications  
 benazepril  
 captopril  
 enalapril  
 fosinopril  
 lisinopril  
 moexipril  
 perindopril  
 quinapril  
 ramipril  
 trandolopril 
ACEI Combination Products  
 amlodipine & benazepril  
 benazepril & HCTZ  
 captopril & HCTZ  
 enalapril & HCTZ  
 enalapril & felodipine  
 fosinopril & HCTZ  
 lisinopril & HCTZ  
 moexipril & HCTZ  
 lisinopril & nutritional supplement  
 quinapril & HCTZ  
 trandolopril-verapamil HCL 
ARB Combination Products 
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 candesartan & HCTZ  
 eprosartan & HCTZ  
 telmisartan & amlodipine  
 irbesartan & HCTZ  
 losartan & HCTZ  
 amlodipine & olmesartan  
 olmesartan & HCTZ  
 telmisartan & HCTZ  
 aliskiren & valsartan 
  valsartan & HCTZ  
 amlodipine & valsartan  
 amlodipine & valsartan & HCTZ  
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Table XXa Time-varying predictors for subjects in cohort A (statin therapy) 
 Quarters Observed 
 1 2 3 4 5 6 
  N = 1,091 N = 1,091 N = 1,057 N = 1,030 N = 1,008 N = 977 
Adherent to statin therapy, 
n (%) 
838 76.81 805 73.79 739 69.91 703 68.25 678 67.26 651 66.63 
Number of 
office/outpatient visits, 
mean (SD) 
16.58 13.58 11.88 12.28 10.25 10.20 9.72 10.39 9.63 11.51 9.44 10.40 
Hospitalization visit (any 
cause), n (%) 
144 13.20 83 7.61 67 6.34 48 4.66 46 4.56 42 4.3 
Emergency room visit (any 
cause), n (%) 
185 16.96 123 11.27 104 9.84 88 8.54 82 81.3 80 8.19 
Receipt of PCI and/or 
CABG, n (%) 
55 5.04 17 1.56 9 0.85 5 0.49 9 0.89 11 1.13 
Presence of claim related 
to risk factors, n (%) 
957 87.72 852 78.09 778 73.60 748 72.62 712 70.63 712 72.88 
Presence of claim related 
to low-survival rate 
conditions, n (%) 
190 17.42 180 16.50 156 14.76 136 13.20 142 14.09 146 14.94 
Number of unique 
prescription claims, mean 
(SD) 
10.09 4.12 8.30 4.09 7.96 4.01 8.02 4.17 7.76 4.02 7.67 4.03 
Part D coverage gap, n (%) 323 29.61 410 37.58 461 43.61 416 40.39 360 35.71 325 33.27 
Out of pocket Medicare 
costs, mean (SD) 
538.97 638.73 549.29 693.86 512.62 611.37 486.67 593.53 475.63 1,106.17 448.90 623.65 
Recurrent AMI, n (%) ─ ─ 19 1.74 14 1.32 16 1.55 16 1.59 13 1.33 
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial 
infarction
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Table XXb Time-varying predictors for subjects in cohort A (statin therapy) 
 Quarters Observed 
 7 8 9 10 11 
  N = 960 N = 688 N = 400 N = 186 N = 9 
Adherent to statin therapy, n (%) 641 66.77 456 66.28 274 68.50 121 65.05 5 55.56 
Number of office/outpatient visits, 
mean (SD) 
8.61 10.23 7.84 13.81 7.34 11.57 4.66 6.96 0.22 0.44 
Hospitalization visit (any cause), n 
(%) 
46 4.79 26 3.78 11 2.75 4 2.15 0 0.00 
Emergency room visit (any 
cause), n (%) 
72 7.50 38 5.52 19 4.75 7 3.76 0 0.00 
Receipt of PCI and/or CABG, n 
(%) 
9 0.94 6 0.87 1 0.25 1 0.54 0 0.00 
Presence of claim related to risk 
factors, n (%) 
606 63.13 408 59.3 218 54.50 79 42.47 0 0.00 
Presence of claim related to low-
survival rate conditions, n (%) 
131 13.65 90 13.08 44 11.00 11 5.91 0 0.00 
Number of unique prescription 
claims, mean (SD) 
7.12 4.21 6.69 4.27 6.59 4.09 5.49 4.33 1.11 1.62 
Part D coverage gap, n (%) 320 33.33 271 39.39 177 44.25 82 44.09 4 44.44 
Out of pocket Medicare costs, 
mean (SD) 
385.70 566.82 324.74 570.83 323.69 498.37 196.02 370.02 21.97 33.99 
Recurrent AMI, n (%) 14 1.46 6 0.87 0 0.00 1 0.54 0 0.00 
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial 
infarction 
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Table XXIa Time-varying predictors for subjects in cohort B (β-blocker therapy) 
 Quarters Observed 
 1 2 3 4 5 6 
  N = 1,021 N = 1,020 N = 984 N = 955 N = 930 N = 907 
Adherent to β-blocker 
therapy, n (%) 
782 76.59 704 69.02 654 66.46 614 64.29 603 64.84 593 65.38 
Number of office/outpatient 
visits, mean (SD) 
15.87 12.97 11.27 11.39 9.59 9.27 9.00 9.88 9.16 10.51 8.66 9.93 
Hospitalization visit (any 
cause), n (%) 
134 13.12 72 7.06 66 6.71 37 3.87 45 4.84 35 3.86 
Emergency room visit (any 
cause), n (%) 
164 16.06 112 10.98 79 8.03 74 7.75 69 7.42 60 6.62 
Receipt of PCI and/or 
CABG, n (%) 
52 5.09 17 1.67 10 1.02 4 0.42 12 1.29 10 1.10 
Presence of claim related to 
risk factors, n (%) 
901 88.25 780 76.47 726 73.78 690 72.25 660 70.97 647 71.33 
Presence of claim related to 
low-survival rate conditions, 
n (%) 
163 15.96 151 14.80 136 13.82 112 11.73 123 13.23 117 12.90 
Number of unique 
prescription claims, mean 
(SD) 
9.61 3.83 7.83 3.75 7.49 3.73 7.53 3.77 7.31 3.70 7.34 3.64 
Part D coverage gap, n (%) 268 26.25 336 32.94 414 42.07 372 38.95 311 33.44 275 30.32 
Out of pocket Medicare 
costs, mean (SD) 
519.43 643.85 512.97 631.85 505.13 875.43 451.20 529.84 425.70 543.63 414.82 567.92 
Recurrent AMI, n (%) ─ ─ 19 1.86 14 1.42 12 1.26 16 1.72 9 0.99 
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial 
infarction 
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Table XXIb Time-varying predictors for subjects in cohort B (β-blocker therapy) 
 Quarters Observed 
 7 8 9 10 11 
  N = 893 N = 652 N = 381 N = 168 N = 9 
Adherent to β-blocker therapy, n (%) 581 65.06 422 64.72 256 67.19 115 68.45 6 66.67 
Number of office/outpatient visits, mean (SD) 8.35 10.21 7.17 8.23 7.06 11.74 4.56 6.94 0.33 0.50 
Hospitalization visit (any cause), n (%) 37 4.14 29 4.45 9 2.36 3 1.79 0 0.00 
Emergency room visit (any cause), n (%) 68 7.61 37 5.67 20 5.25 8 4.76 0 0.00 
Receipt of PCI and/or CABG, n (%) 8 0.90 4 0.61 1 0.26 1 0.60 0 0.00 
Presence of claim related to risk factors, n (%) 564 63.16 389 59.66 211 55.38 76 45.24 1 11.11 
Presence of claim related to low-survival rate 
conditions, n (%) 
111 12.43 80 12.27 40 10.50 11 6.55 0 0.00 
Number of unique prescription claims, mean 
(SD) 
6.78 3.96 6.46 3.93 6.08 3.81 5.13 4.08 1.44 1.81 
Part D coverage gap, n (%) 273 30.57 248 38.04 165 43.31 75 44.64 5 55.56 
Out of pocket Medicare costs, mean (SD) 377.37 550.30 313.46 439.95 291.03 432.73 177.32 351.55 15.69 29.79 
Recurrent AMI, n (%) 10 1.12 9 1.38 1 0.26 2 1.19 0 0.00 
SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial 
infarction 
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Table XXIIa Time-varying predictors for subjects in cohort C (ACEI/ARB therapy) 
 Quarters Observed 
 1 2 3 4 5 6 
 N = 1,025 N = 1,025 N = 984 N = 948 N = 921 N = 889 
Adherent to ACEI/ARB 
therapy, n (%) 
771 75.22 748 72.98 683 69.41 623 65.72 585 63.52 549 61.75 
Number of office/outpatient 
visits, mean (SD) 
16.5 14.03 11.9 12.48 10.30 10.83 9.66 11.12 9.74 11.77 9.12 10.39 
Hospitalization visit (any 
cause), n (%) 
145 14.15 90 8.78 71 7.22 48 5.06 51 5.54 41 4.61 
Emergency room visit (any 
cause), n (%) 
173 16.88 132 12.88 93 9.45 87 9.18 85 9.23 78 8.77 
Receipt of PCI and/or 
CABG, n (%) 
48 4.68 18 1.76 10 1.02 5 0.53 8 0.87 10 1.12 
Presence of claim related to 
risk factors, n (%) 
903 88.10 800 78.05 733 74.49 689 72.68 646 70.14 653 73.45 
Presence of claim related to 
low-survival rate conditions, 
n (%) 
165 16.10 153 14.93 130 13.21 111 11.71 123 13.36 126 14.17 
Number of unique 
prescription claims, mean 
(SD) 
10.22 4.15 8.44 4.08 8.04 4.05 8.12 4.10 7.88 4.06 7.80 3.95 
Part D coverage gap, n (%) 327 31.90 378 36.88 448 45.53 400 42.19 338 36.70 305 34.31 
Out of pocket Medicare 
costs, mean (SD) 
520.05 654.91 541.08 678.91 514.90 630.72 482.21 598.59 476.71 1,131.42 455.81 629.62 
Recurrent AMI, n (%) ─ ─ 22 2.15 12 1.22 14 1.48 20 2.17 14 1.57 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; SD, standard deviation; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial infarction 
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Table XXIIb Time-varying predictors for subjects in cohort C (ACEI/ARB therapy) 
 Quarters Observed 
 7 8 9 10 11 
 N = 874 N = 627 N = 366 N = 164 N = 9 
Adherent to ACEI/ARB therapy, n (%) 521 59.61 360 57.42 212 57.92 97 59.15 4 44.44 
Number of office/outpatient visits, mean (SD) 8.45 9.98 7.22 8.51 7.08 11.23 4.32 5.36 0.22 0.44 
Hospitalization visit (any cause), n (%) 45 5.15 36 5.74 8 2.19 3 1.83 0 0.00 
Emergency room visit (any cause), n (%) 67 7.67 34 5.42 17 4.64 6 3.66 0 0.00 
Receipt of PCI and/or CABG, n (%) 10 1.14 6 0.96 1 0.27 2 1.22 0 0.00 
Presence of claim related to risk factors, n (%) 551 63.04 368 58.69 205 56.01 78 47.56 1 1.11 
Presence of claim related to low-survival rate 
conditions, n (%) 
110 12.59 76 12.12 39 10.66 11 6.71 0 0.00 
Number of unique prescription claims, mean 
(SD) 
7.17 4.32 6.74 4.26 6.54 4.13 5.53 4.26 1.67 1.73 
Part D coverage gap, n (%) 311 35.58 257 40.99 175 47.81 72 43.90 6 66.67 
Out of pocket Medicare costs, mean (SD) 388.62 571.93 328.60 468.64 323.40 497.35 185.57 341.48 23.01 33.34 
Recurrent AMI, n (%) 11 1.26 9 1.44 2 0.55 2 1.22 0 0.00 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; SD, standard deviation; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass graft; AMI, acute myocardial infarction 
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Table XXIII Model 2b: Predictors of the hazard of a recurrent AMI 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.49 [0.25, 0.98] 0.0441* 0.57 [0.28, 1.16] 0.1198 0.58 [0.29, 1.14] 0.1157 
71 - 75 years 0.55 [0.29, 1.04] 0.0674 0.47 [0.22, 0.99] 0.0458* 0.48 [0.25, 0.92] 0.0262* 
76 - 80 years 0.51 [0.26, 1.00] 0.0499* 0.47 [0.23, 0.97] 0.0397* 0.42 [0.21, 0.85] 0.0163* 
81 - 85 years 0.65 [0.34, 1.24] 0.1929 0.99 [0.52, 1.89] 0.9858 0.86 [0.46, 1.61] 0.6287 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.05 [0.66, 1.66] 0.8446 1.10 [0.68, 1.79] 0.6923 1.15 [0.73, 1.82] 0.5529 
Female Ref   Ref   Ref   
Ethnicity          
White 1.25 [0.59, 2.65] 0.5598 1.78 [0.70, 4.52] 0.2282 0.85 [0.43, 1.69] 0.6490 
Other 1.03 [0.33, 3.28] 0.9563 1.88 [0.53, 6.74] 0.3316 0.53 [0.16, 1.74] 0.2926 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.80 [0.45, 1.43] 0.4512 0.86 [0.45, 1.63] 0.6412 0.62 [0.33, 1.18] 0.1485 
Midwest 0.65 [0.37, 1.12] 0.1178 0.74 [0.42, 1.29] 0.2851 0.66 [0.38, 1.15] 0.1431 
West 0.39 [0.17, 0.89] 0.0253* 0.60 [0.27, 1.31] 0.1963 0.71 [0.36, 1.43] 0.3398 
South Ref   Ref   Ref   
CCI 1.09 [1.03, 1.16] 0.0051* 1.14 [1.07, 1.22] <.0001* 1.12 [1.06, 1.19] 0.0002* 
Length of Hospital Stay          
< 7 days 1.12 [0.68, 1.86] 0.6514 1.83 [1.01, 3.31] 0.0462* 1.33 [0.79, 2.24] 0.2795 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.41 [0.16, 1.11] 0.0795 0.68 [0.25, 1.85] 0.4438 0.64 [0.24, 1.73] 0.3839 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.47 [027, 0.81] 0.0060* 0.57 [0.33, 0.98] 0.0413* 0.65 [0.40, 1.08] 0.0937 
Prior Angina 1.47 [0.82, 2.63] 0.1963 1.11 [0.55, 2.21] 0.7735 1.47 [0.82, 2.62] 0.1915 
Prior CAD 1.13 [0.69, 1.86] 0.6280 0.96 [0.57, 1.60] 0.8682 1.19 [0.72, 1.97] 0.4881 
Prior Therapy          
Prior Statin Therapy, 0.84 [0.53, 1.35] 0.4756 1.13 [0.69, 1.85] 0.6385 1.18 [0.74, 1.89] 0.4933 
Prior β-blocker Therapy 1.36 [0.85, 2.19] 0.1996 1.39 [0.83, 2.31] 0.2078 1.49 [0.92, 2.40] 0.1062 
Prior ACEI/ARB Therapy 0.93 [0.57, 1.53] 0.7837 1.16 [0.69, 1.94] 0.5735 0.78 [0.48, 1.27] 0.3225 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.67 [0.43, 1.06] 0.0871 0.69 [0.39, 1.20] 0.1901 0.68 [0.40, 1.15] 0.1478 
Not on therapy ─ ─ ─ 0.95 [0.51, 1.79] 0.8808 0.82 [0.45, 1.52] 0.5307 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy          
Adherent 1.25 [0.68, 2.31] 0.4720 1.19 [0.70, 2.01] 0.5231 1.00 [0.55, 1.79] 0.9858 
Not on therapy 1.19 [0.63, 2.24] 0.5971 ─ ─ ─ 0.89 [0.47, 1.67] 0.7080 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.34 [0.75, 2.39] 0.3235 1.29 [0.70, 2.38] 0.4189 1.68 [0.99, 2.84] 0.0528 
Not on therapy 0.85 [0.45, 1.60] 0.6099 0.91 [0.46, 1.77] 0.7698 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
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Table XXIV Model 2b: Predictors of the hazard of death 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.43 [0.26, 0.71] 0.0011* 0.25 [0.15, 0.44] <.0001* 0.41 [0.25, 0.68] 0.0005* 
71 - 75 years 0.43 [0.27, 0.70] 0.0006* 0.29 [0.17, 0.49] <.0001* 0.37 [0.23, 0.59] <.0001* 
76 - 80 years 0.50 [0.31, 0.80] 0.0043* 0.30 [0.19, 0.49] <.0001* 0.44 [0.28, 0.68] 0.0002* 
81 - 85 years 0.69 [0.44, 1.07] 0.0938 0.62 [0.41, 0.96] 0.0305* 0.74 [0.50, 1.11] 0.1484 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.24 [0.89, 1.73] 0.2004 1.38 [0.98, 1.94] 0.0672 1.14 [0.83, 1.58] 0.4147 
Female Ref   Ref   Ref   
Ethnicity          
White 0.93 [0.57, 1.51] 0.7607 1.06 [0.61, 1.82] 0.8424 0.83 [0.53, 1.30] 0.4090 
Other 0.94 [0.46, 1.94] 0.8727 0.92 [0.41, 2.09] 0.8435 0.61 [0.30, 1.25] 0.1759 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.74 [0.47, 1.15] 0.1745 0.77 [0.49, 1.21] 0.2584 0.68 [0.44, 1.04] 0.0721 
Midwest 0.93 [0.63, 1.38] 0.7328 0.77 [0.52, 1.15] 0.1989 0.75 [0.52, 1.11] 0.1482 
West 0.68 [0.41, 1.15] 0.1497 0.59 [0.34, 1.05] 0.0738 0.79 [0.49, 1.27] 0.3362 
South Ref   Ref   Ref   
CCI 1.14 [1.09, 1.19] <.0001* 1.14 [1.09, 1.20] <.0001* 1.12 [1.08, 1.17] <.0001* 
Length of Hospital Stay          
< 7 days 0.94 [0.66, 1.32] 0.7014 0.97 [0.68, 1.39] 0.8763 0.82 [0.60, 1.12] 0.2184 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.25 [0.11, 0.56] 0.0008* 0.40 [0.18, 0.85] 0.0174* 0.28 [0.12, 0.65] 0.0032* 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.29 [0.18, 0.46] <.0001* 0.32 [0.20, 0.51] <.0001* 0.35 [0.23, 0.53] <.0001* 
Prior Angina 1.05 [0.67, 1.67] 0.8225 0.66 [0.38, 1.16] 0.1501 1.07 [0.68, 1.69] 0.7690 
Prior CAD 1.01 [0.70, 1.44] 0.9766 1.19 [0.84, 1.70] 0.3334 1.12 [0.81, 1.56] 0.4896 
Prior Therapy          
Prior Statin Therapy, 0.93 [0.66, 1.30] 0.6548 1.11 [0.78, 1.59] 0.5662 0.90 [0.65, 1.25] 0.5279 
Prior β-blocker Therapy 0.82 [0.59, 1.15] 0.2490 1.10 [0.78, 1.56] 0.5820 0.77 [0.57, 1.05] 0.1033 
Prior ACEI/ARB Therapy 1.26 [0.88, 1.81] 0.2100 1.20 [0.83, 1.73] 0.3243 1.64 [1.14, 2.37] 0.0077* 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.91 [0.65, 1.28] 0.5942 1.11 [0.71, 1.74] 0.6385 1.13 [0.74, 1.74] 0.5714 
Not on therapy ─ ─ ─ 1.70 [1.07, 2.73] 0.0261* 1.69 [1.08, 2.63] 0.0204* 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy          
Adherent 1.07 [0.69, 1.67] 0.7533 1.04 [0.73, 1.48] 0.8314 0.96 [0.63, 1.45] 0.8284 
Not on therapy 1.15 [0.73, 1.80] 0.5440 ─ ─ ─ 1.06 [0.70, 1.60] 0.7947 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.20 [0.78, 1.84] 0.4019 1.28 [0.82, 2.00] 0.2751 1.18 [0.84, 1.66] 0.3344 
Not on therapy 1.03 [0.65, 1.62] 0.9144 1.04 [0.66, 1.65] 0.8571 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
  
1
2
7
 
 
128 
 
Table XXV Model 3b: Predictors of the hazard of a recurrent AMI 
  Cohort A 
 (Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.45 [0.22, 0.91] 0.0267* 0.54 [0.26, 1.11] 0.0915 0.56 [0.28, 1.11] 0.0953 
71 - 75 years 0.51 [0.27, 0.96] 0.0367 0.45 [0.21, 0.95] 0.0353* 0.46 [0.24, 0.88] 0.0196* 
76 - 80 years 0.48 [0.24, 0.95] 0.0356* 0.46 [0.23, 0.95] 0.0351* 0.41 [0.20, 0.84] 0.0140* 
81 - 85 years 0.63 [0.33, 1.21] 0.1645 1.01 [0.53, 1.92] 0.9832 0.83 [0.44, 1.57] 0.5721 
> 85 years Ref   Ref   Ref   
Gender          
Male 1.11 [0.70, 1.77] 0.6591 1.16 [0.71, 1.89] 0.5651 1.14 [0.72, 1.82] 0.5691 
Female Ref   Ref   Ref   
Ethnicity          
White 1.39 [0.65, 2.99] 0.3940 1.84 [0.72, 4.72] 0.2046 0.88 [0.44, 1.75] 0.7140 
Other 1.08 [0.34, 3.44] 0.9001 1.82 [0.50, 6.57] 0.3607 0.55 [0.17, 1.83] 0.3324 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.83 [0.46, 1.48] 0.5245 0.89 [0.47, 1.68] 0.7072 0.65 [0.34, 1.23] 0.1844 
Midwest 0.68 [0.39, 1.19] 0.1761 0.78 [0.44, 1.37] 0.3857 0.68 [0.39, 1.18] 0.1690 
West 0.40 [0.18, 0.91] 0.0294* 0.62 [0.28, 1.36] 0.2322 0.72 [0.36, 1.44] 0.3488 
South Ref   Ref   Ref   
CCI 1.07 [1.00, 1.15] 0.0561 1.12 [1.04, 1.21] 0.0039* 1.10 [1.02, 1.17] 0.0081* 
Length of Hospital Stay          
< 7 days 1.19 [0.72, 1.98] 0.5017 1.85 [1.02, 3.36] 0.0419* 1.38 [0.82, 2.33] 0.2263 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.44 [0.16, 1.18] 0.1018 0.68 [0.25, 1.89] 0.4632 0.64 [0.24, 1.72] 0.3743 
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  Cohort A 
 (Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.49 [0.28, 0.85] 0.0105* 0.59 [0.34, 1.02] 0.0587 0.68 [0.41, 1.13] 0.1327 
Prior Angina 1.33 [0.74, 2.41] 0.3428 1.08 [0.54, 2.16] 0.8199 1.39 [0.77, 2.52] 0.2705 
Prior CAD 1.10 [0.66, 1.81] 0.7176 0.93 [0.56, 1.56] 0.7808 1.16 [0.70, 1.92] 0.5652 
Prior Therapy          
Prior Statin Therapy, 0.81 [0.51, 1.31] 0.3949 1.11 [0.68, 1.83] 0.6801 1.16 [0.72, 1.87] 0.5438 
Prior β-blocker Therapy 1.34 [0.84, 2.15] 0.2233 1.38 [0.83, 2.29] 0.2115 1.46 [0.90, 2.36] 0.1259 
Prior ACEI/ARB Therapy 0.90 [0.55, 1.48] 0.6851 1.11 [0.66, 1.87] 0.6934 0.78 [0.48, 1.27] 0.3214 
          
TIME-VARYING PREDICTORS          
Number of office/outpatient visits 1.01 [0.99, 1.03] 0.5378 1.00 [0.98, 1.03] 0.8509 1.01 [0.99, 1.03] 0.2742 
Hospitalization visit (any cause) 1.23 [0.53, 2.86] 0.6351 1.04 [0.37, 2.89] 0.9417 1.19 [0.54, 2.61] 0.6642 
Emergency room visit (any cause) 1.22 [0.58, 2.57] 0.5954 1.26 [0.56, 2.84] 0.5846 1.11 [0.54, 2.25] 0.7832 
Receipt of PCI and/or CABG 2.56 [0.56, 11.73] 0.2264 2.80 [0.59, 13.34] 0.1975 1.06 [0.14, 8.15] 0.9581 
Presence of claim related to risk factors 1.52 [0.83, 2.79] 0.1782 1.20 [0.66, 2.20] 0.5486 1.12 [0.64, 1.95] 0.6923 
Presence of claim related to low-survival rate 
conditions 
0.87 [0.48, 1.58] 0.6488 0.91 [0.48, 1.75] 0.7780 0.91 [0.49, 1.66] 0.7508 
Number of unique prescription claims 1.05 [0.99, 1.11] 0.1070 1.06 [1.00, 1.13] 0.0628 1.03 [0.97, 1.09] 0.3724 
Part D coverage gap 1.00 [0.63, 1.59] 0.9979 0.90 [0.55, 1.48] 0.6823 0.96 [0.61, 1.51] 0.8564 
Out of pocket Medicare costs† 0.98 [0.94, 1.03] 0.3810 0.99 [0.94, 1.04] 0.5768 1.00 [0.97, 1.03] 0.7566 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.64 [0.40, 1.02]  0.0617 0.64 [0.36, 1.13] 0.1224 0.66 [0.39, 1.13] 0.1305 
Not on therapy ─ ─ ─ 0.95 [0.50, 1.78] 0.8612 0.82 [0.45, 1.52] 0.5339 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy          
Adherent 1.15 [0.62, 2.13] 0.6543 1.10 [0.65, 1.87] 0.7223 0.97 [0.54, 1.75] 0.9114 
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  Cohort A 
 (Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
Not on therapy 1.11 [0.59, 2.11] 0.7488 ─ ─ ─ 0.85 [0.45, 1.61] 0.6195 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.31 [0.73, 2.36] 0.3605 1.22 [0.66, 2.26] 0.5282 1.64 [0.97, 2.78] 0.0670 
Not on therapy 0.89 [0.47, 1.68] 0.7077 0.92 [0.47, 1.80] 0.8044 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
†Costs were divided by 100 
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Table XXVI Model 3b: Predictors of the hazard of death 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
BASELINE COVARIATES             
Age          
65 - 70 years 0.34 [0.20, 0.58] <.0001* 0.23 [0.13, 0.41] <.0001* 0.36 [0.22, 0.61] 0.0001* 
71 - 75 years 0.34 [0.21, 0.56] <.0001* 0.25 [0.15, 0.43] <.0001* 0.32 [0.20, 0.51] <.0001* 
76 - 80 years 0.41 [0.25, 0.67] 0.0004* 0.29 [0.18, 0.47] <.0001* 0.42 [0.27, 0.66] 0.0001* 
81 - 85 years 0.65 [0.42, 1.02] 0.0591 0.61 [0.39, 0.94] 0.0247* 0.70 [0.46, 1.04]  0.0782 
>  85 years Ref   Ref   Ref   
Gender          
Male 1.24 [0.89, 1.74] 0.2091 1.39 [0.97, 1.97] 0.0708 1.07 [0.77, 1.48] 0.6837 
Female Ref   Ref   Ref   
Ethnicity          
White 1.07 [0.65, 1.75] 0.7893 1.05 [0.61, 1.81] 0.8708 0.93 [0.59, 1.46] 0.7523 
Other 1.16 [0.56, 2.39] 0.6971 0.95 [0.41, 2.19] 0.8963 0.77 [0.38, 1.60] 0.4883 
Black Ref   Ref   Ref   
Region of US          
Northeast 0.79 [0.51, 1.24] 0.3134 0.85 [0.53, 1.35] 0.4842 0.77 [0.50, 1.19] 0.2354 
Midwest 0.97 [0.65, 1.43] 0.8580 0.80 [0.54, 1.19] 0.2694 0.79 [0.53, 1.16] 0.2191 
West 0.76 [0.46, 1.28] 0.3038 0.70 [0.40, 1.25] 0.2285 0.89 [0.55, 1.44] 0.6373 
South Ref   Ref   Ref   
CCI 1.07 [1.02, 1.13] 0.0066* 1.05 [1.00, 1.12] 0.0708 1.05 [1.00, 1.10] 0.0491* 
Length of Hospital Stay          
< 7 days 1.10 [0.77, 1.56] 0.5943 1.06 [0.73, 1.52] 0.7729 0.92 [0.67, 1.27] 0.6190 
≥ 7 days Ref   Ref   Ref   
Surgical Procedure          
CABG 0.31 [0.14, 0.68] 0.0039* 0.30 [0.13, 0.68] 0.0039* 0.27 [0.11, 0.65] 0.0036* 
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
PCI 0.31 [0.19, 0.49] <.0001* 0.33 [0.20, 0.52] <.0001* 0.37 [0.24, 0.56] <.0001* 
Prior Angina 0.98 [0.61, 1.57] 0.9428 0.71 [0.40, 1.24] 0.2255 0.97 [0.61, 1.55] 0.9125 
Prior CAD 0.93 [0.65, 1.34] 0.7009 1.07 [0.74, 1.53] 0.7336 1.09 [0.78, 1.52] 0.6244 
Prior Therapy          
Prior Statin Therapy, 0.91 [0.64, 1.29] 0.6027 1.03 [0.72, 1.49] 0.8638 0.86 [0.62, 1.20] 0.3870 
Prior β-blocker Therapy 0.79 [0.57, 1.10] 0.1624 1.19 [0.84, 1.69] 0.3255 0.74 [0.54, 1.00] 0.0534 
Prior ACEI/ARB Therapy 1.21 [0.84, 1.74] 0.2993 1.18 [0.82, 1.70] 0.3797 1.54 [1.07, 2.22] 0.0210* 
          
TIME-VARYING PREDICTORS          
Number of office/outpatient visits 1.01 [1.01, 1.02] 0.0017* 1.02 [1.00, 1.03] 0.0040* 1.01 [1.00, 1.02] 0.0412* 
Hospitalization visit (any cause) 2.58 [1.64, 4.05] <.0001* 1.89 [1.14, 3.16] 0.0145* 2.20 [1.43, 3.40] 0.0004* 
Emergency room visit (any cause) 2.36 [1.59, 3.50] <.0001* 1.62 [1.05, 2.49] 0.0294* 1.89 [1.26, 2.82] 0.0019* 
Receipt of PCI and/or CABG 0.47 [0.06, 3.46] 0.4573 1.12 [0.26, 4.79] 0.8770 0.38 [0.05, 2.82] 0.3430 
Presence of claim related to risk factors 0.89 [0.58, 1.35] 0.5720 0.88 [0.58, 1.35] 0.5592 0.90 [0.62, 1.32] 0.5977 
Presence of claim related to low-survival rate 
conditions 
1.28 [0.87, 1.87] 0.2085 1.36 [0.90, 2.05] 0.1452 1.36 [0.93, 1.97] 0.1097 
Number of unique prescription claims 1.06 [1.02, 1.09] 0.0042* 1.08 [1.03, 1.12] 0.0003* 1.07 [1.04, 1.11] 0.0001* 
Part D coverage gap 0.88 [0.63, 1.22] 0.4363 1.01 [0.72, 1.42] 0.9394 0.84 [0.62, 1.14] 0.2699 
Out of pocket Medicare costs† 1.00 [0.98, 1.01] 0.5687 1.01 [1.00, 1.02] 0.1284 0.99 [0.98, 1.02] 0.5919 
Recurrent AMI 0.37 [0.13, 1.03] 0.0579 0.27 [0.08, 0.88] 0.0300* 0.31 [0.11, 0.87] 0.0262* 
          
TIME-VARYING ADHERENCE          
Statin Therapy          
Adherent 0.90 [0.64, 1.28] 0.5542 1.03 [0.66, 1.62] 0.8980 1.06 [0.69, 1.64] 0.7923 
Not on therapy ─ ─ ─ 1.64 [1.02, 2.63] 0.0407* 1.70 [1.09, 2.64] 0.0193* 
Non-adherent Ref   Ref   Ref   
β-blocker Therapy  
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  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
Adherent 0.91 [0.58, 1.42] 0.6791 0.89 [0.62, 1.28] 0.5295 0.86 [0.57, 1.31] 0.4894 
Not on therapy 0.95 [0.61, 1.50] 0.8349 ─ ─ ─ 0.89 [0.59, 1.35] 0.5782 
Non-adherent Ref   Ref   Ref   
ACEI/ARB Therapy          
Adherent 1.12 [0.73, 1.71] 0.6182 1.07 [0.68, 1.67] 0.7790 1.08 [0.77, 1.52] 0.6564 
Not on therapy 1.11 [0.70, 1.75] 0.6621 1.01 [0.64, 1.61] 0.9660 ─ ─ ─ 
Non-adherent Ref     Ref     Ref     
*p<0.05 
HR, Hazards Ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity 
index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease 
†Costs were divided by 100 
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Table XXVII Normalized weights 
  Normalized weights 
Person Quarters Mean Std. Dev. Median Range 
Cohort A (Statin Therapy) 8,497 1.00 4.36 0.67 219.32 
Cohort B (β-blocker Therapy)  7,920 1.00 5.09 0.44 222.44 
Cohort C (ACEI/ARB Therapy) 7,832 1.00 6.46 0.43 353.76 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker 
 
 
 
Figure X Log of normalized weights across quarters in cohort A (statin therapy) 
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Figure XI Log of normalized weights across quarters in cohort B (β-blocker therapy) 
 
Figure XII Log of normalized weights across quarters in cohort C (ACEI/ARB therapy) 
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Table XXVIII Adjusted hazard ratios (HRs) from marginal structural models (MSMs) using normalized weights 
  Cohort A  
(Statin Therapy)  
Cohort B  
(β-blocker Therapy)  
Cohort C  
(ACEI/ARB Therapy)  
 N = 1,091 N = 1,021 N = 1,025 
  HR 95% CI p HR 95% CI p HR 95% CI p 
RECURRENT AMI          
Statin Adherence 0.60 [0.37, 0.95] 0.0312*       
β-blocker Adherence    1.07 [0.7, 1.59] 0.7388    
ACEI/ARB Adherence             1.09 [0.56, 2.15] 0.7960 
             
MORTALITY          
Statin Adherence 0.95 [0.64, 1.39] 0.7789       
β-blocker Adherence    1.03 [0.68, 1.55] 0.8976    
ACEI/ARB Adherence             1.32 [0.78, 2.21] 0.2991 
*p<0.05 
HR, Hazards Ratio; AMI, acute myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker 
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